Ornithine Technical Reports
Ornithine is an amino acid that works to prevent cancer and improve the
immune system. Here are a group of medical studies which describe this role for
Ornithine.
Here are a few definitions that may help:
| Polyamines |
Any compound containing two or more amine groups. |
| potent growth-inhibitory effect |
Something which stops cancer growth |
| ornithine decarboxylase |
Ornithine
Plus
Enzymes which can help the body remove carbon dioxide |
| ODC |
ornithine decarboxylase |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
Top
| Number |
Title |
Comments |
|
...1... |
Transport of thyroid hormones to target tissues.
|
|
|
...2... |
Biochemical and growth-modulatory effects of the new S-adenosylmethionine
decarboxylase inhibitor CGP 48664 in malignant and immortalized normal human breast
epithelial cells in culture. |
|
|
...3... |
Structure-activity relations of S-adenosylmethionine
decarboxylase inhibitors on the growth of MCF-7 breast cancer cells.
|
|
|
...4... |
Polyamine profiles and growth properties of ornithine
decarboxylase overexpressing MCF-7 breast cancer cells in culture.
|
|
|
...5... |
Prevention of breast cancer in premenopausal women.
|
|
|
...6... |
Antiproliferative effect of curcumin (diferuloylmethane) against human
breast tumor cell lines. |
|
|
...7... |
Can arginine and ornithine support gut
functions? |
"Dietary ornithine supplementation, in
the form of ornithine alpha-ketoglutarate (OKG) can be
considered as an arginine precursor. Several supplement studies have shown both amino
acids to promote growth hormone and insulin secretion with anabolic effects in
postoperative patients." |
|
...8... |
Chlorpheniramine inhibits the synthesis of ornithine
decarboxylase and the proliferation of human breast cancer cell lines [published erratum
appears in Breast Cancer Res Treat 1996;37(1):97]
|
|
|
...9... |
Intrinsic and extrinsic factors in estrogen action in human breast cancer:
role of polyamines and pituitary factors. |
|
|
..10... |
Ornithine alpha-ketoglutarate in nutritional
support. |
|
|
..11... |
Role of ornithine decarboxylase in
proliferation of prolactin-dependent lymphoma cells.
|
|
|
..12... |
Synthesis and biological evaluation of superactive agonists of growth
hormone-releasing hormone. |
|
|
..13... |
Effects of parathyroid hormone-related peptide on adenosine
3',5'-monophosphate and ornithine decarboxylase in a human
colonic cell line. |
|
|
..14... |
Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate,
ornithine decarboxylase, and cell growth in a human colon
cell line. |
|
|
..15... |
Characterization and growth factor stimulation of L-arginine transport in
a human colon cancer cell line. |
|
|
..16... |
Epidermal growth factor labeled beta-amanitin-poly-L-ornithine:
preparation and evidence for specific cytotoxicity.
|
|
|
...17... |
Role of polyamines in the growth of hormone-responsive and -resistant
human breast cancer cells in nude mice. |
|
|
..18... |
Growth hormone testing for the diagnosis of growth hormone deficiency in
childhood: a population register-based study.
|
|
|
...19... |
Insulin induction of ornithine decarboxylase.
Importance of mRNA secondary structure and phosphorylation of eucaryotic initiation
factors eIF-4B and eIF-4E. |
|
|
..20... |
Polyamine involvement in the growth of hormone-responsive and -resistant
human breast cancer cells in culture. |
|
| |
Middle
Of The Menu |
|
|
..21... |
Polyamine involvement in the secretion and action of TGF-alpha in hormone
sensitive human breast cancer cells in culture.
|
|
|
..22... |
Failure of commercial oral amino acid supplements to increase serum growth
hormone concentrations in male body-builders.
|
|
|
..23... |
Cellular and molecular basis of intestinal and pancreatic adaptation.
|
|
|
..24... |
Effects of parathyroid hormone on ornithine
decarboxylase activity in human osteosarcoma cells.
|
|
|
..25... |
Variations in amplification and expression of the ornithine
decarboxylase gene in human breast cancer cells.
|
|
|
..26... |
Comparison of growth hormone response to growth hormone-releasing factor
1-44 according to the combined study of sleep secretion with the responses to
pharmacologic stimuli. |
|
|
..27... |
Statistical study of 5473 results of nine pharmacological stimulation
tests: a proposed weighting index. |
|
|
..28... |
Human promyelocytic cell line HL60 has the specific binding sites for
prolactin and its ornithine decarboxylase, DNA synthesis and
cellular proliferation are induced by prolactin.
|
|
|
..29... |
Retinoic acid regulates ornithine
decarboxylase gene expression at the transcriptional level. |
|
|
..30... |
Low-dose amino acid supplementation: no effects on serum human growth
hormone and insulin in male weightlifters.
|
|
|
..31... |
Analogues of luteinizing hormone-releasing hormone containing cytotoxic
groups. |
|
|
..32... |
Role of gastrin as a trophic hormone.
|
|
|
..33... |
Regulation of rat ornithine decarboxylase
mRNA translation by its 5'-untranslated region.
|
|
|
..34... |
Direct analysis of growth factor requirements for isolated human fetal
hepatocytes. |
|
|
..35... |
Regulation of ornithine decarboxylase gene
expression in MCF-7 breast cancer cells by antiestrogens.
|
|
|
..36... |
Involvement of the polyamine pathway in antiestrogen-induced growth
inhibition of human breast cancer. |
|
|
..37... |
Intestinal adaptation in short-bowel syndrome.
|
|
|
..38... |
Effects of estradiol on proliferation of endometrial adenocarcinoma cells
(Ishikawa line). |
|
|
..39... |
Sensory deprivation stress and supplemental stimulation in the rat pup and
preterm human neonate. |
|
HealthGate Documents
Record 1 from database: MEDLINE
Return To The Top
- Title
- Transport of thyroid hormones to target tissues.
- Author
- Ekins RP; Sinha AK; Pickard MR; Evans IM; al Yatama F
- Address
- Division of Molecular Endocrinology, University College London Medical School, United
Kingdom.
- Source
- Acta Med Austriaca, 1994, 21:2, 26-34
- Abstract
- Endemic iodine deficiency is associated with maternal hypothyroxinemia and a relatively
high incidence of neurological disorders in the offspring. The previous assumption that
the placenta is impermeable to maternal thyroid hormone, has resulted in the erroneous
suggestion that iodine per se has an essential role in brain development. Furthermore, the
observed factorial rise in thyroxine-binding globulin (TBG) in pregnancy has often been
misinterpreted as preventing thyroid hormone loss to either the fetal compartment or
excretory systems. However, physiochemical analysis of the role of specific binding
proteins in hormone delivery, combined with epidemiological evidence and evolutionary
considerations has led us to postulate that a) maternal thyroxine (T4) is transported to
the fetus, and is of crucial importance in early fetal development, and b) TBG forms part
of a control system specifically designed to maintain at an optimal level the T4
environment to which the developing fetus is exposed. Placental transfer of maternal T4 in
a variety of mammalian species (including humans) is now well established. Further
experimental studies in rats have shown that perturbation of the intrauterine thyroid
hormone environment during critical phases of brain development results in a spectrum of
biochemical dysgenesis. For example, in fetal brains deriving from hypothyroxinemic (Tx)
rat dams, severe disruption of phosphate metabolism is observed and the ontogenesis of two
enzyme activities associated with growth control, protein kinase C and ornithine decarboxylase, are compromised. Development of brain
function is also impaired, as evidenced by the dysgenesis of certain neurotransmitter
metabolic activities (choline acetyltransferase and DOPA decarboxylase).(ABSTRACT
TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 95091118
- MeSH Heading (Major)
- Fetal Development|*PH; Goiter, Endemic|*PP; Maternal-Fetal Exchange|*PH; Thyroid
Hormones|*BL
- MeSH Heading
- Animal; Brain|EM; Carrier Proteins|PH; Female; Fetal Organ Maturity|PH; Human; Infant,
Newborn; Membrane Proteins|PH; Pregnancy; Rats; Support, Non-U.S. Gov't; Thyroid Gland|EM;
Thyroxine|BL; Thyroxine-Binding Proteins|PH
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0303-8173
- Country of Publication
- AUSTRIA
Record 2 from database: MEDLINE
Return To The Top
- Title
- Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase
inhibitor CGP 48664 in malignant and immortalized normal human breast epithelial cells in
culture.
- Author
- Manni A; Badger B; Wechter R; Kunselman S; Rossini A; Demers L
- Address
- Department of Medicine, Pennsylvania State University College of Medicine, Hershey
17033, USA.
- Source
- Int J Cancer, 1995 Aug, 62:4, 485-91
- Abstract
- CGP 48664 [4-aminoindanon-1-(2'-amidino)hydrazone dihydrochloride monohydrate] is a
newly introduced inhibitor of S-adenosylmethionine decarboxylase (SAMDC) with increased
selectivity of action and reduced toxicity. We analyzed the biochemical and
antiproliferative effects of this compound in a panel of hormone-dependent (3 clones of
MCF-7, T47D) and -independent (MDA-MB-231, BT-20) human breast cancer cell lines in
culture. For comparison, we also tested its effects in the spontaneously immortalized
human breast epithelial cell line MCF-10A. All cell lines were highly sensitive to the
growth-inhibitor effect of CGP 48664 with an IC50 between 0.1 and 0.5 microM. A
dose-dependent bell-shaped increase in SAMDC was observed in normal and malignant breast
cells resulting from enzyme stabilization by the inhibitor as supported by Western blot
analysis. While ornithine decarboxylase (ODC) activity
consistently increased, the effect of CGP 48664 on spermidine/spermine N'acetyltransferase
(SSAT) was variable in the breast cancer cell lines. In contrast, the inhibitor
consistently reduced SSAT activity level in the MCF-10A cell line and its derivative
partially transformed by a mutated ras oncogene. As expected cellular putrescine levels
were markedly increased by CGP 48664 administration, whereas spermidine and spermine
contents were reduced. However, the degree of reduction was usually only moderate.
Furthermore, exogenous polyamine administration was relatively ineffective in rescuing the
antiproliferative effect of CGP 48664 in MCF-7 cells, while exerting a more complete
rescue in the MDA-MB-231 cell line. We conclude that CGP 48664 exerts a potent
growth-inhibitory effect on mammary cells in culture. However, its action may not always
be entirely mediated through the polyamine pathway.
- Language of Publication
- English
- Unique Identifier
- 95362369
- MeSH Heading (Major)
- Acetyltransferases|*ME; Adenosylmethionine Decarboxylase|*AI; Amidines|*PD;
Breast|*DE/EN/PA; Breast Neoplasms|*DT/EN/PA; Indans|*PD; Ornithine Decarboxylase|*ME
- MeSH Heading
- Cell Division|DE; Cell Line, Transformed; Dose-Response Relationship, Drug; Drug
Screening Assays, Antitumor; Human; Neoplasms, Hormone-Dependent|DT; Spermidine|ME/PD;
Spermine|PD; Support, U.S. Gov't, P.H.S.; Tumor Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0020-7136
- Country of Publication
- UNITED STATES
Record 3 from database: MEDLINE
Return To The Top
- Title
- Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the
growth of MCF-7 breast cancer cells.
- Author
- Thomas T; Faaland CA; Adhikarakunnathu S; Thomas TJ
- Address
- Department of Environmental & Community Medicine, Environmental and Occupational
Health Sciences Institute, New Brunswick, NJ, USA.
- Source
- Breast Cancer Res Treat, 1996, 39:3, 293-306
- Abstract
- SAMDC is a key enzyme in the biosynthesis of spermidine and spermine, 2 polyamines that
are essential for cell proliferation. Inhibition of polyamine biosynthesis is often
targeted as a therapeutic strategy to suppress cancer cell growth as these cells contain
elevated levels of polyamines. We examined the effect of a new group of SAMDC inhibitors,
CGP33829, CGP35753, CGP36958, CGP39937, and CGP48664, (obtained from Ciba-Geigy, Basel,
Switzerland), and their parent compound, MGBG, on the proliferation of MCF-7 breast cancer
cells. MGBG had minimal effects on the proliferation of MCF-7 cells up to 6 microM
concentration. In contrast, CGP48664 and CGP39937, containing 2 aromatic rings that
delocalize the pi electron system of the backbone of MGBG, were potent inhibitors with 50%
growth inhibition at 0.5 microM concentration. Other CGP compounds were less effective in
inhibiting cell growth. The ability of CGP48664 to inhibit MCF-7 cell proliferation was
related to its ability to inhibit SAMDC and to consequently deplete spermidine and
spermine levels in the cell. Exogenous spermidine and spermine could reverse the growth
inhibitory effects of this compound. CGP compounds also increased the activity of ODC,
another enzyme involved in polyamine biosynthesis. Northern blot analysis of mRNA from
MCF-7 cells progressing in cell cycle after G1 synchronization did not show an increase in
ODC mRNA level by CGP48664. These data demonstrate structure-activity relationships of a
series of MGBG derivatives on cell growth, enzyme activities, and polyamine biosynthesis
in a hormone-responsive breast cancer cell line and suggest potential application of SAMDC
inhibitors as therapeutic agents.
- Language of Publication
- English
- Unique Identifier
- 97031083
- MeSH Heading (Major)
- Adenosylmethionine Decarboxylase|*AI/GE; Antineoplastic Agents|*PD; Breast
Neoplasms|*DT/PA; Enzyme Inhibitors|*PD
- MeSH Heading
- Acetyltransferases|ME; Amidines|PD; Biogenic Polyamines|AN; Cell Division|DE;
Estradiol|PD; Female; Human; Indans|PD; Mitoguazone|PD; Ornithine Decarboxylase|ME; RNA,
Messenger|AN; Structure-Activity Relationship; Support, U.S. Gov't, P.H.S.; Tumor Cells,
Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6806
- Country of Publication
- NETHERLANDS
Record 4 from database: MEDLINE
Return To The Top
- Title
- Polyamine profiles and growth properties of ornithine
decarboxylase overexpressing MCF-7 breast cancer cells in culture.
- Author
- Manni A; Wechter R; Grove R; Wei L; Martel J; Demers L
- Address
- Department of Medicine, Pennsylvania State University College of Medicine, Hershey
17033, USA.
- Source
- Breast Cancer Res Treat, 1995 Apr, 34:1, 45-53
- Abstract
- To determine the direct influence of the polyamine (PA) pathway on breast cancer
phenotype, we employed a transfection approach to induce overexpression of the PA
biosynthetic enzyme ornithine decarboxylase (ODC) in the
hormone-responsive MCF-7 breast cancer cell line. Using a modified calcium phosphate
method and an ODC cDNA coding for a truncated and more stable enzyme, we were able to
achieve a moderate to marked degree of ODC overexpression (up to 150-fold) in a transient
transfection system. ODC-overexpressing MCF-7 cells exhibited a selective increase in
cellular putrescine content, while the levels of spermidine and spermine remained
unaffected. Under defined culture conditions, overexpression of ODC resulted in a
consistent but modest increase in [3H]thymidine incorporation into DNA which was similar
in the presence and absence of 17-beta-estradiol, TGF-alpha, and IGF-I. In the presence of
serum, the effect of ODC overexpression on basal [3H]-thymidine incorporation into DNA was
inconsistent, possibly as a result of subtle differences in culture conditions. Overall,
our results support the hypothesis that activation of the PA biosynthetic pathway may
confer a growth advantage to breast cancer cells.
- Language of Publication
- English
- Unique Identifier
- 95268110
- MeSH Heading (Major)
- Breast Neoplasms|*EN/GE/PA; Ornithine Decarboxylase|GE/*ME
- MeSH Heading
- Cell Division; Female; Gene Expression Regulation, Enzymologic; Human; Polyamines|ME;
Support, U.S. Gov't, P.H.S.; Transfection; Tumor Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6806
- Country of Publication
- NETHERLANDS
Record 5 from database: MEDLINE
Return To The Top
- Title
- Prevention of breast cancer in premenopausal women.
- Author
- Love RR
- Address
- University of Wisconsin Comprehensive Cancer Center, Department of Human Oncology,
Madison 53706.
- Source
- J Natl Cancer Inst Monogr, 1994, :16, 61-5
- Abstract
- While all-inclusive complete models for breast cancer development are not available,
four concepts are likely to be critical to creation of well-grounded breast cancer
prevention efforts: 1) step-by-step progressive development, 2) involving multiple
factors, 3) over several years, and 4) during a long period of which the process may be
reversible. Interventions to prevent breast cancer must have a comprehensive biological
rationale, an absence of serious toxic effects, and long-term acceptability by women.
Prophylactic mastectomy may be beneficial in some women, but identification of individuals
at very high risk for breast cancer remains elusive. At present, greater attention to four
manipulable risk factors is appropriate: radiation, smoking, alcohol, and lactation.
Clinical trials are in the process of studying a synthetic retinoid
(4-hydroxyphenylretinamide), tamoxifen, and a low-fat diet. Other breast cancer prevention
strategies in various phases of preclinical trial evaluation include: pseudopregnancy, an
"ideal" combination oral contraceptive, luteinizing hormone-releasing hormone
(LHRH) agonist oophorectomy, modification of estrogen metabolism, suppression of ornithine decarboxylase induction, and manipulation of growth
factors.
- Language of Publication
- English
- Unique Identifier
- 95092435
- MeSH Heading (Major)
- Breast Neoplasms|EP/ET/*PC
- MeSH Heading
- Adult; Ataxia Telangiectasia|CO; Cocarcinogenesis; Contraceptives, Oral, Hormonal|AE/TU;
Dietary Fats|AD/AE; Estrogens|ME; Female; Fenretinide|PD; Gonadorelin|AG; Human;
Lactation; Mastectomy; Neoplasms, Radiation-Induced|PC; Ornithine Decarboxylase|AI;
Premenopause; Prospective Studies; Pseudopregnancy|CI; Randomized Controlled Trials; Risk
Factors; Smoking; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Tamoxifen|TU;
Temperance; Time Factors
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 1052-6773
- Country of Publication
- UNITED STATES
Record 6 from database: MEDLINE
Return To The Top
- Title
- Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell
lines.
- Author
- Mehta K; Pantazis P; McQueen T; Aggarwal BB
- Address
- Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center,
Houston 77030, USA.
- Source
- Anticancer Drugs, 1997 Jun, 8:5, 470-81
- Abstract
- Pharmacologically safe compounds that can inhibit the proliferation of tumor cells have
potential as anticancer agents. Curcumin, a diferuloylmethane, is a major active component
of the food flavor turmeric (Curcuma longa) that exhibits anticarcinogenic properties in
vivo. In vitro, it suppressed c-jun/Ap-1 and NF-kappaB activation and type 1 human
immunodeficiency virus long-terminal repeat-directed gene expression. We examined the
antiproliferative effects of curcumin against several breast tumor cell lines, including
hormone-dependent and -independent and multidrug-resistant (MDR) lines. Cell growth
inhibition was monitored by [3H]thymidine incorporation, Trypan blue exclusion, crystal
violet dye uptake and flow cytometry. All the cell lines tested, including the
MDR-positive ones, were highly sensitive to curcumin. The growth inhibitory effect of
curcumin was time- and dose-dependent, and correlated with its inhibition of ornithine decarboxylase activity. Curcumin preferentially arrested
cells in the G2/S phase of the cell cycle. Curcumin-induced cell death was neither due to
apoptosis nor to any significant change in the expression of apoptosis-related genes,
including Bcl-2, p53, cyclin B and transglutaminase. Overall our results suggest that
curcumin is a potent antiproliferative agent for breast tumor cells and may have potential
as an anticancer agent.
- Language of Publication
- English
- Unique Identifier
- 97358515
- MeSH Heading (Major)
- Antineoplastic Agents|*PD; Breast Neoplasms|*PA; Curcumin|*PD
- MeSH Heading
- Antibiotics, Anthracycline|PD; Blotting, Western; Cell Cycle|DE; Cell Division|DE; Cell
Line; Doxorubicin|PD; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening
Assays, Antitumor; Human; Ornithine Decarboxylase|ME; Support, Non-U.S. Gov't; Tetrazolium
Salts; Thiazoles
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0959-4973
- Country of Publication
- ENGLAND
Record 7 from database: MEDLINE
Return To The Top
- Title
- Can arginine and ornithine support gut functions?
- Author
- Cynober L
- Address
- Laboratoire de Biochimie, HÈopital Saint-Antoine, Paris, France.
- Source
- Gut, 1994 Jan, 35:1 Suppl, S42-5
- Abstract
- Arginine and ornithine are precursors of nitric oxide and
polyamines, respectively. These metabolites intimately participate in permeability and
adaptive responses of the gut. The liver possesses high arginase activity as an intrinsic
part of urea synthesis and would consume most of the portal supply of dietary arginine.
The gut reduces this possibility by converting dietary arginine to citrulline, which
effectively bypass the liver and is resynthesized to arginine in the kidney. Dietary ornithine supplementation, in the form of ornithine
alpha-ketoglutarate (OKG) can be considered as an arginine precursor. Several supplement
studies have shown both amino acids to promote growth hormone and insulin secretion with
anabolic effects in postoperative patients. Their intermediary metabolites (for example,
glutamine, proline) may also be of benefit in trauma metabolism. Specific effects of
either amino acid on the gut are poorly reported. One recent animal study showed improved
morphology after OKG administration, perhaps through increased polyamine secretion.
Generation of nitric oxide from arginine has two facets. Excess production from high dose
arginine potentiated the effects of experimentally induced sepsis, whereas low doses
improved survival. These considerations suggest that the role of enteral diet
supplementation with arginine or OKG should be urgently examined for any benefits it may
have on mucosal barrier function.
- Language of Publication
- English
- Unique Identifier
- 94171129
- MeSH Heading (Major)
- Arginine|*ME/PD; Enteral Nutrition|*; Intestines|DE/ME/*PH; Ornithine|*ME/PD
- MeSH Heading
- Citrulline|ME; Human; Nitric Oxide|ME
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0017-5749
- Country of Publication
- ENGLAND
Record 8 from database: MEDLINE
Return To The Top
- Title
- Chlorpheniramine inhibits the synthesis of ornithine
decarboxylase and the proliferation of human breast cancer cell lines [published erratum
appears in Breast Cancer Res Treat 1996;37(1):97]
- Author
- Medina MA; García de Veas R; Morata P; Lozano J; Sánchez Jiménez F
- Address
- Laboratorio de BioquÆimica y BiologÆia Molecular, Facultad de Ciencias, Universidad de
MÆalaga, Spain.
- Source
- Breast Cancer Res Treat, 1995 Aug, 35:2, 187-94
- Abstract
- Proliferation of both mouse and human breast cancer cells was inhibited by
chlorpheniramine (CPA) in a dose-response manner. At the beginning of the exponential
phase of growth (two days after seeding), 250 microM CPA was able to reduce cell
proliferation by 75% (in Ehrlich cell cultures) and 30% (in MCF-7 cultures). The
antiproliferative effect of CPA was also tested on a poorly-differentiated and
hormone-insensitive human breast cancer cell line (MDA-MB231) and on a highly
proliferative human colon cancer cell line (clone 3). CPA was cytotoxic for MDA-MB231
cells at concentrations higher than 50 microM, and it was also cytotoxic for the colon
cancer cell clone 3 at 250 microM CPA. Nevertheless, colon cancer cells were slightly
stimulated at CPA concentrations less than 100 microM. CPA reduced (by 50-70%) the ornithine decarboxylase induction occurring early after culture
seeding of experimental mammary tumors (Ehrlich carcinoma cells) and human breast cancer
cells (MCF-7). The presented data suggest that in addition to ODC inhibition, CPA presents
other still unknown cytotoxic effects.
- Language of Publication
- English
- Unique Identifier
- 95375276
- MeSH Heading (Major)
- Breast Neoplasms|*EN/PA; Chlorpheniramine|*PD; Ornithine Decarboxylase|*BI/GE
- MeSH Heading
- Animal; Cell Division|DE; Colonic Neoplasms|EN/GE/PA; Dose-Response Relationship, Drug;
Gene Expression Regulation, Enzymologic|DE; Human; Mammary Neoplasms,
Experimental|EN/GE/PA; Mice; RNA, Messenger|GE; Support, Non-U.S. Gov't; Tumor Cells,
Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6806
- Country of Publication
- NETHERLANDS
Record 9 from database: MEDLINE
Return To The Top
- Title
- Intrinsic and extrinsic factors in estrogen action in human breast cancer: role of
polyamines and pituitary factors.
- Author
- Shiu RP; Lima G; Leung CK; Dembinski TC
- Address
-
- Source
- J Steroid Biochem, 1986 Jan, 24:1, 133-8
- Abstract
- Although polyamines are important in regulating proliferation of mammalian cells, their
role in hormone induction of cell growth has not been delineated. In the
estradiol-responsive human breast cancer cell line, T-47D clone 11, estradiol (10(-10) M)
was able to stimulate cell proliferation and the activity of
- decarboxylase (ODC), the first and rate-limiting enzyme in the biosynthesis of
polyamines. alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the
estradiol-induced cell proliferation and ODC activity. Exogenous addition of putrescine,
the natural product of ODC, rescued the inhibitory effect of DFMO. In addition, DFMO
abolished the estradiol-induced growth of several other estrogen-responsive human breast
cancer cell lines but did not affect the growth of hormone-independent cell lines.
Further, a serum factor was found to be required for estradiol to exert its effect. To
gain insight into the nature of this and possibly other extrinsic factors involved, the
effect of estradiol on the proliferation of T-47D cells transplanted into athymic nude
mouse was evaluated. In this in vivo system, estradiol alone produced only moderate growth
of the human breast tumor. The simultaneous transplantation of a prolactin (PRL)- and
growth hormone (GH)-secreting rat pituitary tumor or normal rat pituitary glands at a
different site dramatically potentiated the effect of estradiol on the growth of the
breast tumor xenograft. Purified PRL or GH were without effect, indicating that the active
pituitary factor is neither PRL nor GH. Further, conditioned medium from rat pituitary
tumor cells potentiated the mitogenic effect of estradiol on T-47D and several other
estrogen receptor-positive human breast cancer cell lines in vitro under serum-free
condition. In conclusion, we have identified both intrinsic (polyamines) and extrinsic
(pituitary/serum) factors that are importance for estrogen to exert its mitogenic action.
The next goal will be to elucidate the mechanisms of action of these molecules in the
modulation of estrogen action.
- Language of Publication
- English
- Unique Identifier
- 86201682
- MeSH Heading (Major)
- Breast Neoplasms|*PA; Estrogens|*PD; Pituitary Gland|*PH; Polyamines|*ME
- MeSH Heading
- Animal; Cell Line; Drug Synergism; Female; Human; Mice; Mice, Nude; Neoplasm
Transplantation; Ornithine|AA/PD; Ornithine Decarboxylase|AN; Pituitary Neoplasms|SE;
Support, Non-U.S. Gov't; Transplantation, Heterologous
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0022-4731
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Estrogens); 0 (Polyamines); 70052-12-9
(Eflornithine); 7006-33-9 (Ornithine)
Record 10 from database: MEDLINE
Return To The Top
- Title
- Ornithine alpha-ketoglutarate in nutritional support.
- Author
- Cynober L
- Address
- Laboratoire de Biochimie, Hopital Saint Antoine, Paris, France.
- Source
- Nutrition, 1991 Sep-Oct, 7:5, 313-22
- Abstract
- Ornithine alpha-ketoglutarate (OKG) is a salt formed of two
molecules of ornithine and one molecule of
alpha-ketoglutarate. OKG has been successfully used by the enteral and parenteral route in
burn, traumatized, and surgical patients and in chronically malnourished subjects.
According to the metabolic situation, OKG treatment decreases muscle protein catabolism
and/or increases synthesis. In addition, OKG promotes wound healing. The mechanism of
action of OKG is not fully understood, but the secretion of anabolic hormones (insulin,
human growth hormone) and the synthesis of metabolites (glutamine, polyamines, arginine,
ketoacids) may be involved.
- Language of Publication
- English
- Unique Identifier
- 92208515
- MeSH Heading (Major)
- Nutrition|*; Ornithine|*AA/AD/AE/CH/ME/PK/TU
- MeSH Heading
- Animal; Chemistry, Physical; Enteral Nutrition; Human; Nutrition Disorders|TH;
Parenteral Nutrition; Wound Healing
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0899-9007
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 37339-58-5 (ornicetil); 7006-33-9 (Ornithine)
Record 11 from database: MEDLINE
Return To The Top
- Title
- Role of ornithine decarboxylase in proliferation of
prolactin-dependent lymphoma cells.
- Author
- Elsholtz HP; Shiu RP; Friesen HG
- Address
-
- Source
- Biochem Cell Biol, 1986 May, 64:5, 381-6
- Abstract
- Mitogenic stimulation of Nb2 lymphoma cells by lactogenic hormones (prolactin, human
growth hormone) caused a dramatic early increase in ornithine
decarboxylase (ODC) activity that achieved a maximal level by 6-8 h. A marked increase in
ODC activity was also generated when cells which had reached a growth plateau were
transferred to fresh medium that did not stimulate growth. Furthermore, low concentrations
of human growth hormone (20 pg/mL) elicited a proliferative response, but did not cause a
detectable early increase in ODC activity. The early peak of ODC activity thus appeared
not to be directly involved in mediating lactogen-stimulated growth nor was it required to
support the mitogenic response. However, prolonged suppression of ODC activity by
DL-alpha-difluoromethylornithine (DFMO) (200 microM) attenuated the growth of Nb2 cells
(50-60% inhibition), indicating that normal cell growth was dependent on ODC and polyamine
biosynthesis. Under these conditions, putrescine, the enzyme product, or the polyamines
spermidine and spermine restored normal cell growth when added at a concentration of 1
microM or greater. Nb2-SP cells, variants which proliferate in the absence of prolactin,
were about two times more resistant to the growth suppressive effects of DFMO than
prolactin-responsive Nb2 cells.
- Language of Publication
- English
- Unique Identifier
- 86242765
- MeSH Heading (Major)
- Lymphoma|EN/*PA; Ornithine Decarboxylase|AI/*ME; Prolactin|*PD; Somatotropin|*PD
- MeSH Heading
- Animal; Cell Division|DE; Cell Line; Human; Kinetics; Ornithine|AA/PD; Support, Non-U.S.
Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0829-8211
- Country of Publication
- CANADA
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 70052-12-9 (Eflornithine); 7006-33-9 (Ornithine);
9002-62-4 (Prolactin); 9002-72-6 (Somatotropin)
Record 12 from database: MEDLINE
Return To The Top
- Title
- Synthesis and biological evaluation of superactive agonists of growth hormone-releasing
hormone.
- Author
- Izdebski J; Pinski J; Horvath JE; Halmos G; Groot K; Schally AV
- Address
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70146,
USA.
- Source
- Proc Natl Acad Sci U S A, 1995 May, 92:11, 4872-6
- Abstract
- Analogs of the 29 amino acid sequence of human growth hormone-releasing hormone (hGH-RH)
with agmatine (Agm) in position 29, desaminotyrosine (Dat) in position 1, norleucine (Nle)
in position 27, and L-alpha-aminobutyric acid (Abu) in position 15 have been synthesized,
and their biological activity was evaluated. Some peptides contained one or two residues
of ornithine (Orn) instead of Lys in positions 12 and 21 and
additional replacements in positions 8 and 28. All analogs were found to be more potent
than hGH-RH-(1-29)-NH2 in the superfused rat pituitary cell system. In tests in vivo in
rats after subcutaneous administration, the analogs JI-22, [Dat1, Orn12,21, Abu15, Nle27,
Agm29]hGH-RH-(1-29); JI-34, [Dat1, Orn12,21,Abu15,Nle27, Asp28, Agm29]hGH-RH-(1-29);
JI-36, [Dat1, Thr8, Orn12,21, Abu15,Nle27,Asp28,Agm29]hGH-RH-(1-29); and JI-38,
[Dat1,Gln8, Orn12,21,Abu15,Nle27,Asp28,Agm29]hGH-RH-(1 -29) displayed a potency
44.6,80.9,95.8, and 71.4 times greater, respectively, than that of hGH-RH-(1-29)-NH2 at 15
min and 217.1, 89.7, 87.9, and 116.8 times greater at 30 min. After intravenous
administration, JI-22, JI-36, and JI-38 were 3.2-3.8 times more potent than
hGH-RH-(1-29)-NH2 at 5 min and 6.1-8.5 times more active at 15 min. All analogs were found
to have higher binding affinities for GH-RH receptors on rat pituitary cells than
hGH-RH-(1-29)-NH2. Because of high activity and greater stability, these analogs could be
considered for therapy of patients with growth hormone deficiency.
- Language of Publication
- English
- Unique Identifier
- 95281558
- MeSH Heading (Major)
- Oligopeptides|CS/*PD; Pituitary Gland|DE/*SE; Somatotropin|BL/*SE;
Somatotropin-Releasing Hormone|*AA/AG/*CS/PD
- MeSH Heading
- Amino Acid Sequence; Animal; Comparative Study; Human; In Vitro; Male; Molecular
Sequence Data; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide|ME; Receptors,
Pituitary Hormone-Regulating Hormone|ME; Structure-Activity Relationship; Support, U.S.
Gov't, Non-P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0027-8424
- Country of Publication
- UNITED STATES
Record 13 from database: MEDLINE
Return To The Top
- Title
- Effects of parathyroid hormone-related peptide on adenosine 3',5'-monophosphate and ornithine decarboxylase in a human colonic cell line.
- Author
- Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM Jr; Cooper CW
- Address
- Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston
77550.
- Source
- Endocrinology, 1992 Apr, 130:4, 1993-2000
- Abstract
- PTH-related peptide (PTHrP) is widely distributed in normal tissues, including the gut,
and is considered a potential autocrine or paracrine regulator of cellular growth and
differentiation. With this in mind, a human colonic cell line (LoVo) was used to study the
effect of PTHrP on ornithine decarboxylase (ODC), because ODC
is known to have profound effects on the growth and differentiation of many cell types via
stimulation of synthesis of polyamines. cAMP also was measured, because this second
messenger has been implicated in the regulation of ODC activity. Nearly confluent LoVo
cells, grown in F-12 medium and 10% fetal bovine serum (FBS), were preincubated in 1% FBS
for at least 5 h, and then PTHrP-(1-34) was added, and the incubation was continued for up
to 6 h. Cell extracts were analyzed for ODC activity by measuring 14CO2 liberated from
14C-labeled ornithine, for cAMP by RIA, and for ODC mRNA by
Northern analysis. PTHrP produced dose-related increases in both cAMP (2- to 3-fold) and
ODC (3- to 5-fold), with a maximal effect at 0.1-1 microM and an ED50 of 1-10 nM.
Comparison of the cAMP and ODC responses to PTHrP showed a strong correlation (r = 0.96; P
less than 0.001). The effects of 1 microM PTHrP-(1-34) to increase cAMP and ODC were
completely inhibited by 10-20 microM of the specific antagonist [Asn10,Leu11]PTHrP-(7-34).
PTHrP-(1-34) did not stimulate ODC activity when cells were incubated without FBS. The
stimulation of ODC activity by PTHrP-(1-34) was maximal at 2 h, a time at which an
increase in ODC mRNA also was evident. PTH-(1-34) and forskolin also stimulated ODC
activity, but PTHrP-(67-86) amide was ineffective. The results indicate that the
N-terminal portion of the PTHrP molecule can stimulate ODC activity in a human colon cell
line and that the effect is probably mediated by cAMP. The results are consistent with the
idea that PTHrP may influence cell growth and differentiation in the gut via an effect on
polyamine biosynthesis. Since LoVo cells also express PTHrP mRNA, this gastrointestinal
cell line may serve as a useful model for studying autocrine regulation of gut cell growth
and differentiation by PTHrP.
- Language of Publication
- English
- Unique Identifier
- 92191895
- MeSH Heading (Major)
- Colon|CH/*DE; Cyclic AMP|*AN; Ornithine Decarboxylase|*AN/GE; Parathyroid Hormones|*PD;
Proteins|GE/*PD
- MeSH Heading
- Cell Line; Human; Peptide Fragments|PD; RNA, Messenger|AN; Support, U.S. Gov't, P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0013-7227
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (parathyroid hormone-related protein); 0
(Parathyroid Hormones); 0 (Peptide Fragments); 0 (Proteins); 0 (RNA, Messenger);
112540-82-6 (hypercalcemic hormone of malignancy (1-34)); 52232-67-4 (Teriparatide);
60-92-4 (Cyclic AMP)
Record 14 from database: MEDLINE
Return To The Top
- Title
- Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell
line.
- Author
- Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM Jr; Cooper CW
- Address
- Department of Pharmacology, University of Texas Medical Branch, Galveston 77550.
- Source
- Endocrinology, 1992 Sep, 131:3, 1188-94
- Abstract
- Vasoactive intestinal peptide (VIP) is a widely distributed neuropeptide that has been
considered a potential regulator of cell growth and differentiation in various tissues,
including the gut. To examine this idea, we used a human colon carcinoma cell line (LoVo)
as a model system and measured ornithine decarboxylase (ODC),
because this is the rate-limiting enzyme for the formation of polyamines, which are
thought to be key factors in regulating cell growth. LoVo cells, grown to about 80%
confluence in F-12 medium containing 10% fetal bovine serum, were preincubated for 5 h in
low serum medium (1% fetal bovine serum in F-12), and ODC activity was determined by
measuring 14CO2 liberated from 14C-labeled ornithine. VIP
caused a dose-related biphasic change in ODC, with activity increased at 10 pM, maximal
(5-fold increase) at 10 nM, and decreased toward basal at 100 nM to 1 microM. Incubation
of cells for 6 days with VIP in low serum medium showed similar changes in cell numbers,
with growth being increased by doses in the 1 pM to 100 nM range and decreased at higher
doses (greater than or equal to 100 nM). Exposure of cells to 5 mM alpha-difluoromethylornithine blocked both the VIP-induced increase in cell number and
the VIP-induced increase in ODC activity. Increased ODC mRNA was detected after 2 h of
exposure to VIP, a time at which ODC activity peaked after treatment, and the increase in
ODC mRNA caused by VIP was dose-dependent. In related experiments LoVo cells were found to
have high affinity VIP receptors (Kd = 0.4 nM), as assessed by examination of [125I]VIP
binding in the presence of varying concentrations of unlabeled VIP. Studies of
intracellular cAMP revealed a dose-related increase in cAMP in response to VIP (ED50 = 11
pM), and the adenylate cyclase activator forskolin increased both ODC activity and ODC
mRNA. The findings support the idea that LoVo cells have VIP receptors linked to cAMP
which can stimulate cell growth at least in part by increasing ODC synthesis and activity,
thereby altering the production of polyamines. The decreased growth and ODC activity
observed with high doses of VIP may involve a second messenger other than cAMP.
- Language of Publication
- English
- Unique Identifier
- 92371314
- MeSH Heading (Major)
- Cell Division|*DE; Cyclic AMP|*ME; Ornithine Decarboxylase|GE/*ME; Vasoactive Intestinal
Peptide|ME/*PD
- MeSH Heading
- Adenocarcinoma; Blotting, Northern; Cell Line; Colonic Neoplasms; Dose-Response
Relationship, Drug; Eflornithine|PD; Human; Kinetics; Receptors, Gastrointestinal
Hormone|ME; RNA, Messenger|ME; RNA, Neoplasm|GE/IP; Support, U.S. Gov't, P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0013-7227
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Receptors, Gastrointestinal Hormone); 0
(Receptors, Vasoactive Intestinal Peptide); 0 (RNA, Messenger); 0 (RNA, Neoplasm);
37221-79-7 (Vasoactive Intestinal Peptide); 60-92-4 (Cyclic AMP); 70052-12-9
(Eflornithine)
Record 15 from database: MEDLINE
Return To The Top
- Title
- Characterization and growth factor stimulation of L-arginine transport in a human colon
cancer cell line.
- Author
- Cendan JC; Souba WW; Copeland EM 3rd; Lind DS
- Address
- Department of General Surgery, University of Florida College of Medicine, Gainesville
32610, USA.
- Source
- Ann Surg Oncol, 1995 May, 2:3, 257-65
- Abstract
- BACKGROUND: Epidermal growth factor (EGF) and transforming growth factor alpha (TGF
alpha) are potent mitogens that contribute to abnormal growth regulation in colon cancer.
Growth factors have been shown to regulate transmembrane nutrient uptake as an adaptive
response to support cellular proliferation. METHODS: The transport of L-arginine by the
SW480 primary human colon adenocarcinoma cell line was characterized by assaying the
uptake of [3H]L-arginine in the presence and absence of sodium. Kinetic studies were
performed over a range of L-arginine concentrations to determine transport affinity (Km)
and maximal transport velocity (Vmax). To further characterize the specific transporters,
[3H]L-arginine uptake was measured in the presence of selected amino acids, hormones, and
under conditions of varying external pH. To investigate the effects of EGF and TGF alpha,
cells were incubated with increasing doses of growth factors (1, 10, 50 ng/ml) and
L-arginine transport was measured at various time intervals (8, 12, 24 h). Proliferation
was assessed by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay 3 days after growth factor stimulation. RESULTS: The majority of
carrier-mediated L-arginine transport was via a sodium-independent process (65-70%),
whereas the remainder was sodium-dependent (28-30%). Diffusion contributed a small amount
to total L-arginine uptake (2%). Kinetic studies of arginine transport revealed a single
high-affinity Na(+)-independent transporter with a Km = 55.8 +/- 5.8 microM and a Vmax =
710.6 +/- 87.3 pM/mg protein/30 s. Na(+)-independent arginine uptake was pH-insensitive
and markedly inhibited by system y+ substrates L-homoarginine, L-lysine, and L-ornithine. A single Na(+)-dependent transporter with a Km = 19.8
+/- 2.3 microM and a Vmax = 159.1 +/- 8.9 pM/mg protein/30 s was identified.
Na(+)-dependent arginine uptake was inhibited by system BO,+ substrates L-lysine, L-ornithine, L-leucine, L-cysteine, and L-glutamine, but not by
2-methylaminoisobutyric acid. In addition, Na(+)-dependent arginine uptake was pH- and
hormone-insensitive. Incubation with EGF or TGF alpha had no effect on Na(+)-independent
L-arginine uptake; however, Na(+)-dependent uptake was enhanced 60% by EGF (10 ng/ml, p
< 0.05) and 100% by TGF alpha (10 ng/ml, p < 0.05), whereas cellular proliferation
was increased 27% by EGF (10 ng/ml, p < 0.05) and 37% by TGF alpha (10 ng/ml, p <
0.01). CONCLUSIONS: L-arginine transport in the SW480 colon cancer cell line is
principally mediated by the Na(+)-independent system y+ and to a lesser extent by the
Na(+)-dependent system BO,+. Furthermore, EGF and TGF alpha preferentially stimulate
L-arginine uptake via the Na(+)-dependent transporter, ostensibly to accommodate for the
mitogenic stimulus.
- Language of Publication
- English
- Unique Identifier
- 95368445
- MeSH Heading (Major)
- Adenocarcinoma|*ME; Arginine|*PK; Colonic Neoplasms|*ME; Epidermal Growth
Factor-Urogastrone|CH/*PD; Transforming Growth Factor alpha|CH/*PD
- MeSH Heading
- Amino Acids|PD; Carrier Proteins; Cell Division|DE; Cell Membrane Permeability|DE;
Human; Hydrogen-Ion Concentration; Ion Channel Gating|DE; Nitric Oxide|BI; Radioisotopes;
Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Time Factors; Tumor Cells,
Cultured|ME
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 1068-9265
- Country of Publication
- UNITED STATES
Record 16 from database: MEDLINE
Return To The Top
- Title
- Epidermal growth factor labeled beta-amanitin-poly-L-ornithine:
preparation and evidence for specific cytotoxicity.
- Author
- Bermbach U; Faulstich H
- Address
- Max-Planck-Institut für medizinische Forschung, Abteilung Physiologie, Heidelberg, West
Germany.
- Source
- Biochemistry, 1990 Jul 24, 29:29, 6839-45
- Abstract
- Poly-L-ornithine with an average molecular weight of 32K was reacted with beta-amanitin
hydroxysuccinimide ester to form an amide-linked toxin conjugate. Loading of the polymeric
chain with amanitin was high, corresponding to up to 35% of the total weight. To this
amatoxin vehicle we attached a targeting molecule, human recombinant leucine-21 epidermal
growth factor (hrEGFL), via a disulfide-containing linker moiety. A typical average
stoichiometry of the hrEGFL labeled toxin conjugate was
(L-Orn)164(beta-amanitin)19(COC2H4SSC2H4CO-hrEGFL)2. The affinity for EGF receptors of
hrEGFL bound in this conjugate was tested by using A 431 cells. The affinity was eight
times lower than that of unsubstituted hrEGFL but regarded as high enough for studying
specific toxicity effects with cells bearing EGF receptors. We found that beta-amanitin in
the labeled conjugate was able to inhibit the growth of A 431 cells at a concentration of
28 nM, 80 times lower than for native beta-amanitin and 20 times lower than for poly-L-ornithine-bound beta-amanitin without the hrEGFL label. The
approximately 20-fold enhancement of cytotoxicity suggests a specific internalization of
the toxin conjugate mediated by the hormone label. This idea is supported by the fact that
also in another transformed fibroblast cell line, with an increased though smaller number
of EGF receptors than A 431 cells, the corresponding enhancement of cytotoxicity was
demonstrable but less pronounced (7-fold). The hormone-mediated increase in cytotoxicity
of EGF labeled poly-L-ornithine-beta-amanitin conjugates,
combined with their moderate toxicity in the mouse, encourages further examination of such
compounds in tumor model systems in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 90373797
- MeSH Heading (Major)
- Amanitins|*/TO; Epidermal Growth Factor-Urogastrone|*/ME; Peptides|*
- MeSH Heading
- Animal; Cytotoxins; Human; Receptors, Epidermal Growth Factor-Urogastrone|ME; Support,
Non-U.S. Gov't; Tumor Cells, Cultured|DE/ME
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0006-2960
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Amanitins); 0 (Cytotoxins); 0 (Peptides); 0 (Receptors, Epidermal Growth
Factor-Urogastrone); 21150-22-1 (beta-amanitin); 25104-12-5 (polyornithine); 62229-50-9
(Epidermal Growth Factor-Urogastrone)
Record 17 from database: MEDLINE
Return To The Top
- Title
- Role of polyamines in the growth of hormone-responsive and -resistant human breast
cancer cells in nude mice.
- Author
- Manni A; Badger B; Martel J; Demers L
- Address
- Department of Medicine, Pennsylvania State University, Hershey 17033.
- Source
- Cancer Lett, 1992 Sep 14, 66:1, 1-9
- Abstract
- Recent in vitro data suggest that at least some hormone-independent breast cancer cells
exhibit increased polyamine biosynthesis and resistance to antipolyamine therapy. To
address this issue under conditions of in vivo growth, we tested the antiproliferative
effect of the polyamine synthetic inhibitor alpha-difluoromethyl-ornithine
(DFMO) on hormone-dependent (MCF-7) and -independent (MDA-MB-231, BT-20) breast cancer
cell lines growing in nude mice. We observed that DFMO significantly inhibited the growth
of established tumors to a similar extent in all cell lines, even though tumor regression
was only observed with MCF-7 cells. DFMO, while inhibiting E2-supported MCF-7 breast
cancer growth, did not inhibit E2-stimulated progesterone receptor synthesis. Cellular
levels of polyamines were highest in MCF-7 cells and lowest in the BT-20 cell line. Tumor
content of spermidine was similarly suppressed by DFMO treatment in the 3 cell lines,
while the spermine level was unaffected. Cellular putrescine levels were suppressed in
MCF-7 and BT-20 cells. Administration of DFMO prior to implantation of fragments of MCF-7
or MDA-MB-231 tumors in nude mice significantly inhibited tumor development to a similar
extent. The action of DFMO seemed to be predominantly tumoristatic since new tumors
develop in some mice upon discontinuation of the drug. We conclude that the
hormone-independent breast cancer cell lines tested do not exhibit increased polyamine
biosynthesis or resistance to antipolyamine therapy when grown in vivo in nude mice.
- Language of Publication
- English
- Unique Identifier
- 93082651
- MeSH Heading (Major)
- Breast Neoplasms|DT/*PA/PP; Neoplasms, Hormone-Dependent|DT/*PA/PP; Polyamines|*
- MeSH Heading
- Animal; Cell Division|DE; Comparative Study; Drug Resistance; Drug Screening Assays,
Antitumor; Eflornithine|PD; Human; Mice; Mice, Nude; Neoplasm Transplantation;
Putrescine|ME/PH; Spermidine|ME/PH; Spermine|ME/PH; Support, U.S. Gov't, P.H.S.; Tumor
Cells, Cultured|DE
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0304-3835
- Country of Publication
- NETHERLANDS
- CAS Registry/EC Number
- 0 (Polyamines); 110-60-1 (Putrescine); 124-20-9 (Spermidine); 70052-12-9 (Eflornithine);
71-44-3 (Spermine)
Record 18 from database: MEDLINE
Return To The Top
- Title
- Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a
population register-based study.
- Author
- Carel JC; Tresca JP; Letrait M; Chaussain JL; Lebouc Y; Job JC; Coste J
- Address
- Association France Hypophyse, HÈopital Cochin, Paris, France. jccarel@infobiogen.fr
- Source
- J Clin Endocrinol Metab, 1997 Jul, 82:7, 2117-21
- Abstract
- Evaluation of GH secretion using pharmacological GH stimulation tests (GHST) remains a
current practice, although the reliability of GHST has been questioned, and many pitfalls
have been pointed out. We have analyzed all of the 6373 GH stimulation tests that led to
the initiation of GH therapy in 3233 children treated in France from 1973-1989. Tests and
GH measurements were performed by individual centers and collected by the Association
France-Hypophyse. GH deficiency (GHD) was due to craniospinal irradiation (11%), was due
to organic causes or associated with multiple deficiencies (22%), or was considered
idiopathic (65%); 2% of the patients were considered non-GHD. Eleven different
pharmacological tests were used, and 62 of the 66 theoretical pairs of tests were used at
least once. The most frequent combination of tests (ornithine
in one instance and insulin in another) was used in 12.7% of patients. The reliability of
the GH peak measured by comparing the results of 2 tests in the same patient was poor, as
measured by intraclass correlation coefficients below 0.8. Multivariate analysis
identified several parameters positively or negatively associated with peak plasma GH:
calendar year of initiation of treatment, etiology of GHD, height SD score, bone age SD
score, puberty, weight SD score, genetic target height SD score, and the nature of the
pharmacological agent used. We believe that several of these factors (weight SD score,
genetic target height SD score, and nature of the agent) identify biases in the diagnosis
of GHD. We conclude that GHST should be performed with a very limited number of agents,
interpreted after the establishment of reference values in age-matched normal children,
and associated with other clinical and biochemical parameters for establishing the
diagnosis of GHD.
- Language of Publication
- English
- Unique Identifier
- 97358161
- MeSH Heading (Major)
- Somatotropin|*BL/*DF
- MeSH Heading
- Adolescence; Age Factors; Child; Child, Preschool; Female; Human; Male; Methods;
Registries; Reproducibility of Results; Retrospective Studies
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0021-972X
- Country of Publication
- UNITED STATES
Record 19 from database: MEDLINE
Return To The Top
- Title
- Insulin induction of ornithine decarboxylase. Importance of
mRNA secondary structure and phosphorylation of eucaryotic initiation factors eIF-4B and
eIF-4E.
- Author
- Manzella JM; Rychlik W; Rhoads RE; Hershey JW; Blackshear PJ
- Address
- Howard Hughes Medical Institute Laboratories, Duke University Medical Center, Durham,
North Carolina 27710.
- Source
- J Biol Chem, 1991 Feb 5, 266:4, 2383-9
- Abstract
- We investigated the possibility that insulin could stimulate translation of ornithine decarboxylase (ODC) mRNA in a murine fibroblast cell line
that expresses large numbers of human insulin receptors (HIR 3.5 cells). Within 3 h after
exposure to 70 nM insulin, ODC enzyme activity increased approximately 50-fold and mRNA
accumulation 3-fold in the HIR 3.5 cells but not in normal fibroblasts. Pretreatment of
cells with cycloheximide completely inhibited insulin-stimulated ODC expression;
actinomycin D partially inhibited this effect. To determine the influence of the 5'
untranslated region (5'UTR) of ODC mRNA on insulin-regulated ODC expression, plasmids were
constructed which contained sequences from the 5'UTR of a rat ODC mRNA interposed between
the ferritin promoter and the coding region of the human growth hormone gene. These
constructions were then expressed transiently in HIR 3.5 cells. Insulin stimulated a
2-4-fold change in growth hormone accumulation in the medium of cells transiently
expressing plasmids containing the entire 5'UTR of ODC mRNA or just the 5'-most 115 bases,
a G/C-rich conserved sequence predicted to form a stem-loop structure and shown previously
to be responsible for constitutive inhibition of translation. There was a direct
correlation between the extent of insulin stimulation and the predicted secondary
structure of the added 5'UTR sequences. To determine whether this effect might be due to
insulin activation of initiation factors responsible for melting mRNA secondary structure,
we examined the effect of insulin on the phosphorylation states of two such factors,
eucaryotic initiation factors eIF-4B and eIF-4E. Insulin stimulated the phosphorylation of
both initiation factors; this stimulation was evident at 15 min and maximal by 60 min.
These results suggest a potential general mechanism by which insulin could preferentially
stimulate translation of mRNAs whose 5'UTRs exhibit significant secondary structure by
activating initiation factors involved in melting such secondary structures.
- Language of Publication
- English
- Unique Identifier
- 91115858
- MeSH Heading (Major)
- Insulin|*PD; Ornithine Decarboxylase|*BI/GE; Peptide Initiation Factors|*ME; RNA,
Messenger|*CH/GE
- MeSH Heading
- Animal; Blotting, Northern; Cell Line; Cloning, Molecular; Cycloheximide|PD;
Dactinomycin|PD; Dose-Response Relationship, Drug; Enzyme Induction; Human; Mice; Nucleic
Acid Conformation; Phosphorylation; Receptors, Insulin|ME; Support, Non-U.S. Gov't;
Support, U.S. Gov't, P.H.S.; Translation, Genetic
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0021-9258
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (eIF-4B); 0 (eIF-4E); 0 (Peptide Initiation
Factors); 0 (Receptors, Insulin); 0 (RNA, Messenger); 11061-68-0 (Insulin); 50-76-0
(Dactinomycin); 66-81-9 (Cycloheximide)
Record 20 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Polyamine involvement in the growth of hormone-responsive and -resistant human breast
cancer cells in culture.
- Author
- Glikman P; Manni A; Demers L; Bartholomew M
- Address
- Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University,
Hershey 17033.
- Source
- Cancer Res, 1989 Mar 15, 49:6, 1371-6
- Abstract
- Recent evidence indicates that hormone-responsive but not -resistant human breast cancer
cells in culture are sensitive to the antiproliferative effect of the polyamine (PA)
biosynthetic inhibitor alpha-difluoromethylornithine (DFMO).
The present experiments were designed to investigate the potential differential
involvement of the PA pathway in the growth of these different biological subtypes of
human breast cancer. Thus, we evaluated the effect of DFMO on proliferation, ornithine decarboxylase (ODC) activity, and PA levels of the
hormone-dependent MCF-7 and -independent MDA-MB-231 breast cancer cell lines. When tested
at comparable cell density, the two cell lines had similar levels of ODC activity and PA.
Administration of DFMO (0.01, 0.1, 1, 4 mM) for 6 days caused a similar dose-dependent
inhibition of proliferation (up to approximately 15% of control) associated with
suppression of ODC activity to undetectable levels at the highest dose. In both cell
lines, putrescine and spermidine levels were maximally suppressed by doses of DFMO greater
than 0.1 mM. Higher doses of DFMO (1 and 4 mM) also suppressed spermine levels to
approximately 60% of control. In detailed time-course studies, DFMO administration (0.1
mM) similarly suppressed by 80% the rise in ODC observed in both cell lines following a
medium change. At all time points, putrescine and spermidine levels were likewise
suppressed to a similar extent. Addition of putrescine (0.1-2.5 mM) to DFMO-treated cells
repleted cellular PA levels and restored growth to approximately 80% of control in both
cell lines. We conclude that, under these experimental conditions, PA are similarly
involved in the growth of the hormone-responsive MCF-7 and -resistant MDA-MB-231 human
breast cancer cell lines.
- Language of Publication
- English
- Unique Identifier
- 89168158
- MeSH Heading (Major)
- Biogenic Polyamines|*PH; Breast Neoplasms|*PA; Neoplasms, Hormone-Dependent|*PA
- MeSH Heading
- Cell Count; Dose-Response Relationship, Drug; Eflornithine|PD; Female; Human; Ornithine
Decarboxylase|AN; Putrescine|PD; Support, U.S. Gov't, P.H.S.; Time Factors; Tumor Cells,
Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0008-5472
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Biogenic Polyamines); 110-60-1 (Putrescine);
70052-12-9 (Eflornithine)
Record 21 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Polyamine involvement in the secretion and action of TGF-alpha in hormone sensitive
human breast cancer cells in culture.
- Author
- Kim I; Manni A; Lynch J; Demers L
- Address
- Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University,
Hershey, PA 17033.
- Source
- Breast Cancer Res Treat, 1991 May, 18:2, 83-91
- Abstract
- These experiments were designed to test polyamine (PA) involvement in the secretion and
action of transforming growth factor alpha (TGF-alpha) in hormone responsive MCF-7 breast
cancer cells in liquid culture. At the same time, we evaluated the influence of culture
conditions (with serum vs. serum depleted) and subclonality of MCF-7 cells on PA
involvement in estrogen (E2) and TGF-alpha stimulated cell proliferation. Despite inducing
a profound suppression of cellular PA levels and inhibiting basal and E2-stimulated
growth, administration of the PA synthesis inhibitor alpha-difluoromethylornithine (DFMO) did not influence either basal or E2-induced
TGF-alpha secretion. In the same experiments, on the other hand, addition of DFMO
completely blocked the growth stimulatory effect of exogenous TGF-alpha. However, when the
culture conditions were changed to serum-free medium, TGF-alpha and E2-induced cell
proliferation was affected modestly or not at all by DFMO administration, despite similar
suppression of cellular ornithine decarboxylase (ODC)
activity and PA levels. In addition, different clones of MCF-7 cells differed in their
sensitivity to the antiproliferative effect of DFMO as well as in basal levels of ODC
activity and PA. We conclude that PAs are not involved in basal or E2-stimulated TGF-alpha
secretion in MCF-7 breast cancer cells. On the other hand, PAs do seem to be important
mediators of TGF-alpha and E2-induced breast cancer cell proliferation, though the degree
of such involvement appears to be influenced by serum factors and clonal variability of
MCF-7 cells.
- Language of Publication
- English
- Unique Identifier
- 92004007
- MeSH Heading (Major)
- Breast Neoplasms|*ME/PA; Polyamines|*PD; Transforming Growth Factor alpha|*SE
- MeSH Heading
- Cell Division|DE; Eflornithine|PD; Estrogens|PH; Human; In Vitro; Neoplasms,
Hormone-Dependent; Putrescine|PD/PH; Serum Albumin, Bovine|PD; Spermidine|PH; Spermine|PH;
Support, U.S. Gov't, P.H.S.; Tumor Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6806
- Country of Publication
- NETHERLANDS
- CAS Registry/EC Number
- 0 (Estrogens); 0 (Polyamines); 0 (Serum Albumin, Bovine); 0 (Transforming Growth Factor
alpha); 110-60-1 (Putrescine); 124-20-9 (Spermidine); 70052-12-9 (Eflornithine); 71-44-3
(Spermine)
Record 22 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Failure of commercial oral amino acid supplements to increase serum growth hormone
concentrations in male body-builders.
- Author
- Lambert MI; Hefer JA; Millar RP; Macfarlane PW
- Address
- Dept. of Physiology, University of Cape Town Medical School, South Africa.
- Source
- Int J Sport Nutr, 1993 Sep, 3:3, 298-305
- Abstract
- Amino acids are commonly ingested as ergogenic acids in the belief that they enhance
protein synthesis and stimulate growth hormone release. The aim of this study was to
determine the acute effect that amino acid supplements have on serum growth hormone (GH)
concentration. Seven male body-builders reported to the laboratory on four occasions after
an 8-hr fast and ingested, in random order, either a placebo, a 2.4-g arginine/lysine
supplement, a 1.85-g ornithine/tyrosine supplement, or a 20-g
BovrilR drink. Blood was collected before each treatment and again every 30 minutes for 3
hours for the measurement of serum GH concentration. On a separate occasion, subjects had
an intravenous infusion of 0.5 microgram GH-releasing hormone.kg-1 body weight to confirm
that GH secretory response was normal. The main finding was that serum GH concentrations
were not altered consistently in healthy young males following the ingestion of the amino
acid supplements in the quantities recommended by the manufacturers.
- Language of Publication
- English
- Unique Identifier
- 94035086
- MeSH Heading (Major)
- Amino Acids|AD/*PD; Somatotropin|AD/BL/*DE; Weight Lifting|*PH
- MeSH Heading
- Administration, Oral; Adult; Human; Male; Support, Non-U.S. Gov't
- Publication Type
- CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
- ISSN
- 1050-1606
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Amino Acids); 9002-72-6 (Somatotropin)
Record 23 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Cellular and molecular basis of intestinal and pancreatic adaptation.
- Author
- Dowling RH
- Address
- Gastroenterology Unit, Guy's Hospital, London, U.K.
- Source
- Scand J Gastroenterol Suppl, 1992, 193:, 64-7
- Abstract
- This article reviews the structural and functional changes which develop in the
intestine and pancreas in response to a variety of stimuli and which characterise adaptive
hyper- or hypo-plasia. It then discusses the principal physiological mechanisms
controlling this adaptive growth. In the gut, these include luminal nutrition, endocrine,
autocrine and paracrine hormonal influences, growth factors, enterotrophic components of
pancreatico-biliary secretions, neural factors, changes in blood flow and
mesenchyme-epithelial interactions. The cell biology of adaptive growth involves cell
membrane receptors (first messengers) and a cascade of intracellular second messengers,
the best studied of which is changes in polyamine metabolism and in related enzymes. The
effects of ornithine decarboxylase (ODC) blockade with
difluoromethyl ornithine (DFMO) and of diamine oxidase (DAO)
blockade with aminoguanidine, are described. In general, DFMO inhibits or prevents
adaptive hyperplasia while in the small bowel, aminoguanidine treatment induces
'supranormal' adaptation. However, both the gut and the pancreas transport 'exogenous'
(ingested in food and circulating in the blood stream) polyamines across their apical and
basolateral membranes. The influence of this exogenous polyamine transport on 'endogenous'
(enzyme-regulated) intracellular polyamine concentrations, is largely unknown. Finally,
the molecular biology of adaptive growth is described briefly--as illustrated by the use
of a growth hormone transgenic model in which mice develop marked intestinal mucosal
hyperplasia and increases in the relative abundance of insulin-like growth factor-I
(IGF-I) mRNA in the intestine.
- Language of Publication
- English
- Unique Identifier
- 93174201
- MeSH Heading (Major)
- Adaptation, Physiological|*; Intestines|ME/PA/*PH; Pancreas|ME/PA/*PH
- MeSH Heading
- Amine Oxidase (Copper-Containing)|ME; Animal; Cell Division; Human; Hyperplasia;
Polyamines|ME; RNA, Messenger
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0085-5928
- Country of Publication
- NORWAY
- CAS Registry/EC Number
- EC 1.4.3.6 (Amine Oxidase (Copper-Containing)); 0 (Polyamines); 0 (RNA, Messenger)
Record 24 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Effects of parathyroid hormone on ornithine decarboxylase
activity in human osteosarcoma cells.
- Author
- Goto H; Matsui-Yuasa I; Otani S; Morisawa S; Nishizawa Y; Morii H
- Address
- Department of Biochemistry, Osaka City University Medical School, Japan.
- Source
- Arch Biochem Biophys, 1991 May 1, 286:2, 316-22
- Abstract
- Ornithine decarboxylase (ODC) is a rate-limiting enzyme of
the biosynthesis of polyamines, which are important in cell growth and differentiation.
Here, we studied whether parathyroid hormone (PTH) affects the induction of ODC and the
proliferation of the human osteoblast-like cell line SaOS2, which is sensitive to PTH. In
confluent cells, ODC activity was not detected, but activity was significantly induced by
fresh medium, with maximum activity 6 h after the change. PTH potentiated this enzyme
induction in a dose-dependent manner at 10(-9) and 10(-8) M at which range the
intracellular cAMP level also rose. Dibutyryl cAMP, cholera toxin, and
3-isobutyl-1-methylxanthine each caused an increase in ODC activity similar to that with
PTH. The half-life of enzyme activity was about 30 min and was not changed by the addition
of PTH. mRNA coding for ODC was detected in the confluent cells and its concentration was
increased two- to threefold by the fresh medium. No further increase in mRNA occurred when
PTH was added. At 48 h after the change of medium, PTH inhibited the DNA synthesis induced
by fresh medium. These results suggest that the increase in ODC activity caused by PTH was
caused by enhancement of cAMP synthesis, and that this augmentation involves
post-transcriptional regulation.
- Language of Publication
- English
- Unique Identifier
- 91378318
- MeSH Heading (Major)
- Cyclic AMP|*ME; Ornithine Decarboxylase|*ME; Parathyroid Hormones|*PD; Peptide
Fragments|*PD
- MeSH Heading
- Bucladesine|PD; Butyric Acids|PD; Cell Line; DNA Replication|DE; Eflornithine|PD; Human;
Kinetics; Nucleic Acid Hybridization; Osteosarcoma; Polyamines|ME; RNA, Neoplasm|GE/IP
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0003-9861
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Butyric Acids); 0 (Parathyroid Hormones); 0
(Peptide Fragments); 0 (Polyamines); 0 (RNA, Neoplasm); 107-92-6 (butyric acid); 362-74-3
(Bucladesine); 52232-67-4 (Teriparatide); 60-92-4 (Cyclic AMP); 70052-12-9 (Eflornithine)
Record 25 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Variations in amplification and expression of the ornithine
decarboxylase gene in human breast cancer cells.
- Author
- Thomas T; Kiang DT; Jänne OA; Thomas TJ
- Address
- Department of Environmental and Community Medicine, UMDNJ-Robert Wood Johnson Medical
School, Piscataway 08854.
- Source
- Breast Cancer Res Treat, 1991 Nov, 19:3, 257-67
- Abstract
- The polyamine biosynthetic pathway plays a critical role in the growth of human breast
cancer cells. Ornithine decarboxylase (ODC) is a key enzyme
in polyamine biosynthesis. To understand the regulation of ODC activity and polyamine
accumulation in breast cancer cells, we studied amplification and expression of the ODC
gene in four breast cancer cell lines. ODC gene dosage was analyzed by Southern blot
hybridization and was 4- to 12-fold higher in T-47D, MDA-MB-231, and BT-20 cell lines than
in the MCF-7 cell line. ODC mRNA level was 2- to 3-fold higher in BT-20 and MDA-MB-231
cell lines than in the other two lines. We also measured ODC activity and polyamine
concentration in these cell lines, and determined their sensitivity to an ODC inhibitor,
difluoromethylornithine (DFMO). BT-20 cells showed
significantly higher ODC activity and polyamine concentrations than the other three cell
lines. BT-20 cells were resistant to the growth inhibitory effect of DFMO even at 4 mM
concentration, whereas the proliferation of MCF-7, T47D, and MDA-MB-231 cells was
inhibited by this drug. These results suggest that different transcriptional and
post-transcriptional mechanisms control the regulation of ODC gene expression in breast
cancer cell lines.
- Language of Publication
- English
- Unique Identifier
- 92135858
- MeSH Heading (Major)
- Adenocarcinoma|EN/*PA; Breast Neoplasms|EN/*PA; Carcinoma|EN/*PA; Carcinoma,
Intraductal, Noninfiltrating|EN/*PA; Neoplasm Proteins|BI/*GE; Ornithine
Decarboxylase|BI/*GE
- MeSH Heading
- Comparative Study; DNA, Neoplasm|GE; Eflornithine|PD; Enzyme Induction; Estrogens;
Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Human; Neoplasms,
Hormone-Dependent|EN/PA; Polyamines|AN; RNA, Messenger|BI; RNA, Neoplasm|AN; Support, U.S.
Gov't, P.H.S.; Tumor Cells, Cultured|DE/EN
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0167-6806
- Country of Publication
- NETHERLANDS
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (DNA, Neoplasm); 0 (Estrogens); 0 (Neoplasm
Proteins); 0 (Polyamines); 0 (RNA, Messenger); 0 (RNA, Neoplasm); 70052-12-9
(Eflornithine)
Record 26 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Comparison of growth hormone response to growth hormone-releasing factor 1-44 according
to the combined study of sleep secretion with the responses to pharmacologic stimuli.
- Author
- Garnier P; Liapi C; Raynaud F; Evain-Brion D
- Address
- Fondation de Recherche en Hormonologie, Fresnes, France.
- Source
- Horm Res, 1987, 28:1, 13-9
- Abstract
- The growth hormone (GH) response to GH-releasing factor (GRF) was studied in 54 severely
growth-retarded patients (-2.1 to -6.5 SD) aged from 5 to 20 years (32 males and 22
females), among whom 34 were prepubertal and 20 at early pubertal stages. The patients
were also submitted to a standard evaluation of their GH secretion, consisting of at least
two classical pharmacologic stimulation (CPS) tests, such as ornithine,
arginine and/or insulin, and one study of the GH sleep secretion (SS). The results of the
standard evaluation allowed to distinguish 5 groups: (I) endocrinologically normal (n =
26); (II) completely GH deficient (n = 5); (III) partially GH deficient (n = 8); (IV)
dissociated GH secretions with normal SS (n = 9), and (V) dissociated GH secretions with
low SS (n = 6). The GH responses to GRF were correlated with both responses to CPS and SS.
There was a large overlap of the individual responses to GRF between the 5 groups, but the
mean responses in groups II, IV and V were significantly lower than in group I.
Furthermore, the mean responses of groups IV and V were in the lower range of the normal.
It is concluded that the GRF test may be useful to ascertain the diagnosis of functional
or partial GH deficiency when the responses to CPS and SS are dissociated.
- Language of Publication
- English
- Unique Identifier
- 88197053
- MeSH Heading (Major)
- Growth Disorders|*ME; Sleep|*PH; Somatotropin|DF/*SE; Somatotropin-Releasing Hormone|*DU
- MeSH Heading
- Adolescence; Adult; Child; Child, Preschool; Comparative Study; Female; Human; Male;
Pituitary Function Tests|MT; Pituitary Gland|DE/SE
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0301-0163
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 9002-72-6 (Somatotropin); 9034-39-3 (Somatotropin-Releasing Hormone)
Record 27 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Statistical study of 5473 results of nine pharmacological stimulation tests: a proposed
weighting index.
- Author
- Rochiccioli P; Enjaume C; Tauber MT; Pienkowski C
- Address
- Service de Pédiatrie, CHU Purpan, Toulouse, France.
- Source
- Acta Paediatr, 1993 Mar, 82:3, 245-8
- Abstract
- A total of 5473 pharmacological stimulation tests were carried out in 3143 children and
subjected to statistical analysis. The mean chronological age of the children was 9 years
9 months (range 3 years to 16 years 6 months) and mean bone age was 7 years 6 months
(range 2 years to 14 years). Nine pharmacological tests were used: (1) arginine (n = 625);
(2) clonidine (n = 339); (3) insulin (n = 198); (4) ornithine
(n = 162); (5) insulin and arginine (n = 203); (6) clonidine and betaxolol (n = 2003); (7)
L-dopa (n = 685); (8) glucagon and propranolol (n = 443); and (9) glucagon and betaxolol
(n = 815). Measurement of plasma growth hormone was always performed using the same
method. The distribution of values in each test was of the gausso-logarithmic type. The
results of the mean peak and the 95% confidence limit were as follows: (1) 10.2, 0.45; (2)
11.5, 0.7; (3) 11.8, 0.8; (4) 14.2, 1.2; (5) 14.3, 0.9; (6) 15.7, 1.1; (7) 19.8, 2.1; (8)
20.8, 2.3; (9) 21, 2.5. These results lead to the following conclusions: the specificity
of these tests is low, the mean peak may vary two-fold from one test to another, and the
percentage of peaks < 10 ng/ml ranges from 69% for test 1 to 29% for tests 8 and 9. The
proportion of growth hormone deficiencies thus varies considerably according to the test
used.(ABSTRACT TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 93264725
- MeSH Heading (Major)
- Drugs|*DU; Growth Disorders|BL/*DI
- MeSH Heading
- Adolescence; Child; Child, Preschool; Comparative Study; Female; Human; Male;
Retrospective Studies; Sensitivity and Specificity; Somatotropin|BL/DF
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0803-5253
- Country of Publication
- NORWAY
- CAS Registry/EC Number
- 0 (Drugs); 9002-72-6 (Somatotropin)
Record 28 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Human promyelocytic cell line HL60 has the specific binding sites for prolactin and its ornithine decarboxylase, DNA synthesis and cellular proliferation
are induced by prolactin.
- Author
- Nishiguchi Y; Hibasami H; Komada Y; Sakurai M; Nakashima K
- Address
- Department of Biochemistry, Mie University Faculty of Medicine, Japan.
- Source
- Leuk Res, 1993 Aug, 17:8, 633-7
- Abstract
- Human prolactin (hPRL) induced ornithine decarboxylase
(ODC) activity, subsequently DNA synthesis and cellular proliferation on human
promyelocytic cells, HL60, cultured in a serum-free medium. HL60 cells had 2100 specific
binding sites for hPRL per cell, showing a dissociation constant of 1.1 x 10(-10) M.
Binding of 125I-PRL to the cells was not blocked by simultaneous addition of human growth
hormone. ODC activity and DNA synthesis were activated maximally at 5 and 20 h,
respectively, after the addition of 0.05 nM hPRL. These effects of PRL on cellular
proliferation, ODC activity and DNA synthesis were abolished by the simultaneous addition
of anti-hPRL antibody. Simultaneous addition of an irreversible inhibitor of ODC,
difluoromethyl ornithine (DFMO), also abolished the
inductions of ODC and DNA synthesis by hPRL. The inhibitory effect of DFMO on hPRL-induced
DNA synthesis was reversed by the addition of putrescine to the culture medium. These
results suggest that hPRL binds to the prolactin receptor on HL60 cells and induces ODC
activity to increase cellular polyamine levels, which eventually stimulates DNA synthesis
and cellular proliferation.
- Language of Publication
- English
- Unique Identifier
- 93360545
- MeSH Heading (Major)
- Cell Division|*DE; DNA Replication|*DE; Leukemia, Promyelocytic, Acute|*ME/PA; Ornithine
Decarboxylase|*BI; Prolactin|ME/*PD; Receptors, Prolactin|*BI
- MeSH Heading
- Binding Sites; Carbon Radioisotopes; Dose-Response Relationship, Drug; DNA, Neoplasm|BI;
Enzyme Induction; Human; Iodine Radioisotopes; Kinetics; Thymidine|ME; Tritium; Tumor
Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0145-2126
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Carbon Radioisotopes); 0 (DNA, Neoplasm); 0
(Iodine Radioisotopes); 0 (Receptors, Prolactin); 10028-17-8 (Tritium); 50-89-5
(Thymidine); 9002-62-4 (Prolactin)
Record 29 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Retinoic acid regulates ornithine decarboxylase gene
expression at the transcriptional level.
- Author
- Mao Y; Gurr JA; Hickok NJ
- Address
- Department of Dermatology, Jefferson Institute of Molecular Medicine, Thomas Jefferson
University, Philadelphia, PA 19107.
- Source
- Biochem J, 1993 Nov 1, 295 ( Pt 3):, 641-4
- Abstract
- Retinoic acid (RA) is important for normal mammalian development and growth. Ornithine decarboxylase (ODC) is the first and rate-limiting enzyme
in the biosynthesis of the polyamines, and we have previously shown that ODC mRNA levels
are suppressed by RA in human skin cells. Using HeLa cells, we now show that treatment
with 0.5 microM RA for 24 h suppresses endogenous ODC mRNA levels and the expression of a
transfected ODC/chloramphenicol acetyltransferase plasmid (Kpn-ODCCAT), containing
sequences from -1450 to +810 of the human ODC gene. Co-transfection with either the
alpha-RA receptor (alpha-RAR) or a chimeric alpha-RA/oestrogen receptor (alpha-RAER)
followed by treatment with the cognate hormone suppresses expression of Kpn-ODCCAT and
Not-ODCCAT, which contains sequences from -250 to +514. Liganded alpha-RAR suppresses the
activity of Kpn-ODCCAT more markedly than does liganded alpha-RAER (98% and 80%
suppression, respectively), whereas both receptors have very similar effects on Not-ODCCAT
expression (73% and 67% suppression, respectively). The unliganded alpha-RAR suppresses
Kpn-ODCCAT by 76%, whereas unliganded alpha-RAER has no significant effect. These data
show that RA regulates ODC-gene expression at the transcriptional level, and that
alpha-RAR, but not alpha-RAER, can confer full hormonal responsiveness. This suggests that
the activating function present in the alpha-RAR ligand-binding domain is required for
full transcriptional regulation.
- Language of Publication
- English
- Unique Identifier
- 94059011
- MeSH Heading (Major)
- Gene Expression Regulation|*DE; Ornithine Decarboxylase|*GE; Transcription, Genetic|*DE;
Tretinoin|*PD
- MeSH Heading
- Animal; Blotting, Northern; Cell Line; Cercopithecus aethiops; Hela Cells; Human;
Kidney; Receptors, Estrogen|GE/PH; Receptors, Retinoic Acid|GE/PH; RNA, Messenger|ME;
Support, U.S. Gov't, P.H.S.; Transfection
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0264-6021
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Receptors, Estrogen); 0 (Receptors, Retinoic
Acid); 0 (RNA, Messenger); 302-79-4 (Tretinoin)
Record 30 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Low-dose amino acid supplementation: no effects on serum human growth hormone and
insulin in male weightlifters.
- Author
- Fogelholm GM; Näveri HK; Kiilavuori KT; Härkönen MH
- Address
- Dept. of Applied Chemistry and Microbiology, University of Helsinki, Finland.
- Source
- Int J Sport Nutr, 1993 Sep, 3:3, 290-7
- Abstract
- Using a double-blind, crossover protocol, we studied the possible effects of a 4-day
combined L-arginine, L-ornithine, and L-lysine
supplementation (each 2 g/day, divided into two daily doses) on 24-hr level of serum human
growth hormone (hGH) and insulin in 11 competitive weightlifters, ages 19 to 35 yrs. Three
similar daily hGH peaks, seemingly preceded by a decrease in serum insulin concentration,
were found during both amino acid and placebo supplementation. Supplementation did not
affect the physiological variation of serum hGH concentration (treatment and treatment x
time interaction: p = 0.43-0.55). Analogously, serum insulin levels were not higher after
amino acid supplementation. Therefore the ergogenic value of low-dose oral amino acid
supplementation in increasing hGH or insulin secretion seems questionable.
- Language of Publication
- English
- Unique Identifier
- 94035085
- MeSH Heading (Major)
- Amino Acids|AD/*PD; Somatotropin|BL/*DE; Weight Lifting|*PH
- MeSH Heading
- Adult; Double-Blind Method; Drug Administration Schedule; Human; Insulin|ME; Male;
Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 1050-1606
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Amino Acids); 11061-68-0 (Insulin); 9002-72-6 (Somatotropin)
Record 31 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
- Author
- Janáky T; Juhász A; Bajusz S; Csernus V; Srkalovic G; Bokser L; Milovanovic S; Redding
TW; Rékási Z; Nagy A; et al
- Address
- Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New
Orleans, LA.
- Source
- Proc Natl Acad Sci U S A, 1992 Feb 1, 89:3, 972-6
- Abstract
- In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic
radicals including an alkylating nitrogen mustard derivative of D-phenylalanine
(D-melphalan), reactive cyclopropane, anthraquinone derivatives
[2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an
antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists
of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine6 and D-ornithine6 or N epsilon-(2,3-diaminopropionyl)-D-lysine and N
delta-(2,3-diaminopropionyl)-D-ornithine were used as
carriers for one or two cytotoxic moieties. The enhanced biological activities produced by
the incorporation of D amino acids into position 6 of the agonistic analogues were further
increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with
10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues
showed high affinities for the membrane receptors of human breast cancer cells, while the
receptor binding affinities of peptides containing two cytotoxic side chains were lower.
Antagonistic carriers [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3, Arg5,D-Lys6,D-Ala10] LH-RH [where
Nal(2) is 3-(2-naphthyl)alanine], [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Trp3,Arg5,N
epsilon-(2,3-diaminopropionyl)-D-Lys6,D- Ala10]LH-RH, and their D-Pal(3)3 homologs [Pal(3)
is 3-(3-pyridyl)alanine] as well as [Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,Tyr5,N
epsilon-(2,3-diamino-propionyl)-D-Lys6,D-Ala10]LH-RH were linked to cytotoxic compounds.
The hybrid molecules inhibited ovulation in rats at doses of 10 micrograms and suppressed
LH release in vitro. The receptor binding of cytotoxic analogues was decreased compared to
the precursor peptides, although analogues with 2-(hydroxymethyl)anthraquinone
hemiglutarate had high affinities. All of the cytotoxic analogues tested inhibited
[3H]thymidine incorporation into DNA in cultures of human breast and prostate cancer cell
lines. Some cytotoxic analogues also significantly suppressed the growth of mammary and
prostate cancers in vivo in animal models.
- Language of Publication
- English
- Unique Identifier
- 92141240
- MeSH Heading (Major)
- Cytotoxins|*AD; Gonadorelin|*AA/ME; Hormones, Synthetic|*CH
- MeSH Heading
- Amino Acid Sequence; Animal; Antimetabolites, Antineoplastic|AD; Cell Division|DE;
Human; In Vitro; Molecular Sequence Data; Rats; Receptors, LHRH|ME; Structure-Activity
Relationship; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.; Tumor Cells,
Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0027-8424
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Antimetabolites, Antineoplastic); 0 (Cytotoxins); 0 (Hormones, Synthetic); 0
(Receptors, LHRH); 33515-09-2 (Gonadorelin)
Record 32 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Role of gastrin as a trophic hormone.
- Author
- Walsh JH
- Address
- Center for Ulcer Research and Education, Wadsworth Veterans Administration Center, Los
Angeles, Calif.
- Source
- Digestion, 1990, 47 Suppl 1:, 11-6; discussion 49-52
- Abstract
- Gastrin has two principal biological effects: stimulation of acid secretion from gastric
parietal cells and stimulation of mucosal growth in the acid-secreting part of the
stomach. Circulating gastrin regulates the increase in acid secretion that occurs during
the after meals. Gastrin also stimulates mucosal growth in the stomach. Exogenously
administered gastrin causes increased cell division in the proliferative zone that lies
between the surface cells and the gastric glands in the acid-secreting mucosa. The newly
formed cells undergo differentiation into surface epithelial cells, parietal cells and
gastric enterochromaffin-like cells. Furthermore, the increased mucosal proliferation that
occurs with refeeding after a period of fasting may be mediated by gastrin since refeeding
stimulates gastrin production and a parallel increase in mucosal DNA synthesis. Both food
and gastrin cause a rapid increase in cell division and an increase in gastric ornithine decarboxylase mRNA in fasting rats. In preliminary
immunoneutralization experiments, the stimulation of ornithine
decarboxylase produced by food was inhibited by gastrin antibody. The sustained inhibition
of gastric acid secretion obtained by surgery or with antisecretory drug therapy results
in hypergastrinaemia associated with increased gastric mucosal cell proliferation. A good
correlation between gastric enterochromaffin-like cell density and circulating gastrin
concentrations has been found under these conditions as well as during infusions of
exogenous gastrin. Trophic effects of gastrin have also been reported for the colon,
duodenum and pancreas, but chronic hypergastrinaemia does not appear to produce
hyperplasia of these organs.(ABSTRACT TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 91231139
- MeSH Heading (Major)
- Gastric Acid|*SE; Gastrins|PD/*PH; Parietal Cells, Gastric|*SE
- MeSH Heading
- Animal; Cell Division|DE; Gastric Mucosa|CY/DE; Human; Omeprazole|PD
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0012-2823
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 0 (Gastrins); 73590-58-6 (Omeprazole)
Record 33 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Regulation of rat ornithine decarboxylase mRNA translation
by its 5'-untranslated region.
- Author
- Manzella JM; Blackshear PJ
- Address
- Howard Hughes Medical Institute Laboratories, Duke University Medical Center, Durham,
North Carolina 27710.
- Source
- J Biol Chem, 1990 Jul 15, 265:20, 11817-22
- Abstract
- Ornithine decarboxylase (ODC), a key enzyme in polyamine biosynthesis, is a highly
inducible protein whose expression involves a complex and variable array of regulatory
mechanisms. We investigated the influence of the 5'-untranslated region (5'UTR) of the rat
ODC mRNA on translation of the mRNA in a cell-free system and in cultured mammalian cells.
ODC mRNA containing the full-length 5'UTR was translated in reticulocyte lysates at
approximately 5% of the rate of mRNA containing no ODC 5' leader sequences. The complete
5'UTR inhibited expression of a heterologous gene product, human growth hormone, to the
same extent in cultured mammalian cells. Furthermore, the 5'-most 130 bases of the rat ODC
5'UTR, a conserved G/C-rich region predicted to form a stable stem-loop structure (delta G
= -68 kcal/mol), repressed translation to the same extent as the entire 5'UTR, both in the
lysates and in intact cells. The 3'-most 160 bases of the 5'UTR, containing a small
upstream open reading frame, decreased expression by 50-65% both in vitro and in intact
cells, compared with controls lacking any ODC 5'UTR sequences. Mutation of the initiation
codon AUG beginning this upstream open reading frame to GCG restored expression to rates
equivalent to those seen in constructions containing no ODC 5'UTR sequences. We conclude
that the rat ODC mRNA 5'UTR can inhibit translation of ODC mRNA both in vitro and in vivo,
and that the predicted stem-loop structure at the 5' end of the 5'UTR is both necessary
and sufficient for this inhibition.
- Language of Publication
- English
- Unique Identifier
- 90307705
- MeSH Heading (Major)
- Gene Expression Regulation, Enzymologic|*; Ornithine Decarboxylase|*GE; RNA,
Messenger|*GE; Translation, Genetic|*
- MeSH Heading
- Animal; Calorimetry; Cell Line; Cells, Cultured; Genes, Regulator; Human; Kinetics;
Mice; Mutation; Nucleic Acid Conformation; Plasmids; Promoter Regions (Genetics); Rats;
Restriction Mapping; Reticulocytes|ME; Somatotropin|AN/GE; Support, Non-U.S. Gov't;
Support, U.S. Gov't, P.H.S.; Transfection
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0021-9258
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Plasmids); 0 (RNA, Messenger); 9002-72-6
(Somatotropin)
Record 34 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Direct analysis of growth factor requirements for isolated human fetal hepatocytes.
- Author
- Hoshi H; Kan M; McKeehan WL
- Address
- W. Alton Jones Cell Science Center, Inc., Lake Placid, New York 12946.
- Source
- In Vitro Cell Dev Biol, 1987 Oct, 23:10, 723-32
- Abstract
- Hepatocytes were isolated from human fetal liver in order to analyze the direct effects
of growth factors and hormones on human hepatocyte proliferation and function. Mechanical
fragmentation and then dissociation of fetal liver tissue with a collagenase/dispase
mixture resulted in high yield and viability of hepatocytes. Hepatocytes were selected in
arginine-free, ornithine-supplemented medium and defined by
morphology, albumin production and ornithine uptake into
cellular protein. A screen of over twenty growth factors, hormones, mitogenic agents and
crude organ and cell extracts for effect on the stimulation of hepatocyte growth revealed
that EGF, insulin, dexamethasone, and factors concentrated in bovine neural extract and
hepatoma cell-conditioned medium supported attachment, maintenance and growth of
hepatocytes on a collagen-coated substratum. The population of cells selected and defined
as differentiated hepatocytes had a proliferative potential of about 4 cumulative
population doublings. EGF and insulin synergistically stimulated DNA synthesis in the
absence of other hormones and growth factors. Although neural extracts enhanced hepatocyte
number, no effect on DNA synthesis of neural extracts or purified heparin-binding growth
factors from neural extracts could be demonstrated in the absence or presence of defined
hormones, hepatoma-conditioned medium or serum. Hepatoma cell-conditioned medium had the
largest impact on both hepatocyte cell number and DNA synthesis under all conditions.
Dialyzed serum protein (1 mg/ml) at 10 times higher protein concentration had a similar
effect to hepatoma cell-conditioned medium (100 micrograms/ml). The results suggest that
hepatoma cell conditioned medium may be a concentrated and less complicated source than
serum for purification and characterization of additional normal hepatocyte growth
factors.
- Language of Publication
- English
- Unique Identifier
- 88032740
- MeSH Heading (Major)
- Growth Substances|*PD; Hormones|*PD; Liver|CY/DE/*EM
- MeSH Heading
- alpha-Fetoproteins|AN; Albumins|AN; Arginine|PD; Blood|PH; Cell Adhesion|DE; Cell
Division|DE; Cell Survival; Cells, Cultured; Comparative Study; Culture Media|PD; Drug
Interactions; Human; Support, U.S. Gov't, P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0883-8364
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (alpha-Fetoproteins); 0 (Albumins); 0 (Culture Media); 0 (Growth Substances); 0
(Hormones); 7004-12-8 (Arginine)
Record 35 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Regulation of ornithine decarboxylase gene expression in
MCF-7 breast cancer cells by antiestrogens.
- Author
- Thomas T; Trend B; Butterfield JR; Jänne OA; Kiang DT
- Address
- Department of Environmental and Community Medicine, Robert Wood Johnson Medical School,
University of Medicine and Dentistry of New Jersey, Piscataway 08854.
- Source
- Cancer Res, 1989 Nov 1, 49:21, 5852-7
- Abstract
- Ornithine decarboxylase (ODC) is an enzyme intimately related to cell growth regulation.
The metabolic products of ODC, the polyamines, are known to play a vital role in the
structure and function of biological macromolecules including nucleic acids and proteins.
The activity of ODC is stimulated by estrogens in their target cells. In order to gain
insight into the molecular mechanism of action of antiestrogens in human breast cancer, we
studied the effect of tamoxifen and 4-hydroxytamoxifen on the concentration of ODC mRNA,
ODC activity, and the polyamine levels in a hormone-responsive breast cancer cell line,
MCF-7. ODC mRNA concentration was reduced to 40% of the controls after 6 h of treatment of
the cells with 100 nM 4-hydroxytamoxifen, but tamoxifen had no significant effect on ODC
mRNA after treating with even 1 microM concentration for 36 h. ODC activity was, however,
reduced to 40 and 75% of the controls after 24 h of treatment with 4-hydroxytamoxifen and
tamoxifen, respectively. There was a significant reduction in the concentration of
putrescine to 63% of control in tamoxifen-treated cells, but spermidine and spermine
levels were not affected. With 4-hydroxytamoxifen, putrescine, spermidine, and spermine
levels were reduced to 41, 62, and 79% of the control, respectively. In addition,
exogenous putrescine was able to reverse the growth inhibitory effects of
4-hydroxytamoxifen. Overall, these results indicate that ODC and polyamine levels in MCF-7
cells are controlled by antiestrogens, and that suppression of polyamine biosynthesis
plays a critical role in the growth inhibitory effects of antiestrogens.
- Language of Publication
- English
- Unique Identifier
- 90002952
- MeSH Heading (Major)
- Breast Neoplasms|*EN; Estrogen Antagonists|*PD; Gene Expression Regulation,
Enzymologic|*DE; Gene Expression Regulation, Neoplastic|*DE; Genes, Structural|*DE;
Ornithine Decarboxylase|BI/*GE
- MeSH Heading
- Blotting, Northern; Cell Line; Female; Human; Nucleic Acid Hybridization; Polyamines|ME;
Putrescine|PD; RNA, Messenger|DE/GE; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.;
Tamoxifen|PD; Tumor Cells, Cultured|DE
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0008-5472
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Estrogen Antagonists); 0 (Polyamines); 0 (RNA,
Messenger); 10540-29-1 (Tamoxifen); 110-60-1 (Putrescine); 68392-35-8 (4-hydroxytamoxifen)
Record 36 from database: MEDLINE
Return To The Top
Return To The
Middle Of The Menu
- Title
- Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human
breast cancer.
- Author
- Cohen FJ; Manni A; Glikman P; Bartholomew M; Demers L
- Address
- Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University,
Hershey 17033.
- Source
- Cancer Res, 1988 Dec 1, 48:23, 6819-25
- Abstract
- Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast
cancer cell proliferation, at least in part, through suppression of the polyamine (PA)
pathway. To directly test this hypothesis, we evaluated the effect of TAM administration
on ornithine decarboxylase (ODC) activity, the rate-limiting
enzyme in PA synthesis, as well as cellular PA levels in the hormone-responsive MCF-7
breast cancer cell line in culture. In detailed time course studies, we observed that TAM
significantly inhibited the rise in ODC activity observed in control cells following a
medium change. Chronic treatment with escalating amounts of TAM caused a dose-related
decrease in tumor pools of putrescine and spermidine, while spermine levels were
unaffected. The TAM effects on ODC activity and PA pools were reversible with exogenous
estradiol administration. However, addition of putrescine to TAM-treated cells did not
result in a reversal of the antiproliferative effect of TAM, despite repletion of cellular
PA pools. Administration of TAM to the hormone-independent MDA-MB-231 breast cancer cell
line did not suppress ODC activity or cellular PA levels despite induction, at high
concentrations, of an estradiol-irreversible inhibition of proliferation. We conclude
that, in the hormone-responsive MCF-7 breast cancer cell line, TAM causes a significant
suppression of the PA pathway, the relation of which, if any, to its antiproliferative
action remains obscure. This effect seems to be mediated through the estrogen receptor and
does not appear to be a nonspecific consequence of inhibition of cell proliferation.
- Language of Publication
- English
- Unique Identifier
- 89028354
- MeSH Heading (Major)
- Biogenic Polyamines|*ME; Breast Neoplasms|EN/*PA; Tamoxifen|*PD
- MeSH Heading
- Cell Division|DE; Dose-Response Relationship, Drug; Estradiol|PD; Female; Human;
Ornithine Decarboxylase|ME; Polyamines|PD; Support, U.S. Gov't, P.H.S.; Tumor Cells,
Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0008-5472
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Biogenic Polyamines); 0 (Polyamines);
10540-29-1 (Tamoxifen); 50-28-2 (Estradiol)
Record 37 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Intestinal adaptation in short-bowel syndrome.
- Author
- Lentze MJ
- Address
- Abteilung für pädiatrische Gastroenterologie, Medizinische Universitäts-Kinderklinik,
Bern, Switzerland.
- Source
- Eur J Pediatr, 1989 Jan, 148:4, 294-9
- Abstract
- After massive resection of the small intestine the remnant mucosa has an important
capacity to enlarge the absorptive surface for the digestion, hydrolysis and absorption of
nutrients. This intestinal adaptation is achieved by the interaction of various factors.
Oral nutrients together with pancreatic biliary secretions stimulate the mucosa to become
hyperplastic. Secondary to these luminal factors hormones play an important role in the
adaptive process. Among the hormones, enteroglucagon is the most important growth
promoting agent together with other growth factors such as epidermal growth factor,
prostaglandin E2 and human growth hormone analogues, e.g. plerocercoid growth factor from
the plerocercoid larvae of the tapeworm Spirometra mansonoides. The intestinal enterocyte
is the target of these factors and within the cell the synthesis of polyamines, which are
responsible for rapid growth, is the most essential step for the development of
hyperplasia after resection. The rate limiting enzyme for polyamine synthesis ornithine decarboxylase (ODC) reacts to trophic stimuli with an
increased activity. Thereafter rapid accumulation of tissue polyamines occurs. Blockade of
ODC by specific inhibitors is accompanied by absence of intestinal hyperplasia after
resection. Therefore it is concluded that ODC plays a key role in the intestinal
adaptation of the remnant small bowel. To start and enhance intestinal hyperplasia after
resection in patients with short bowel syndrome introduction of oral nutrition as soon as
possible after operation is very important. On account of gastric acid hypersecretion the
use of H2 receptor blocking agents is recommended. A decreased intestinal transit time is
treated with loperamide.(ABSTRACT TRUNCATED AT 250 WORDS)
- Language of Publication
- English
- Unique Identifier
- 89210965
- MeSH Heading (Major)
- Intestinal Absorption|*; Malabsorption Syndromes|*PP; Short Bowel Syndrome|*PP
- MeSH Heading
- Child; Human; Intestinal Mucosa|PP
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0340-6199
- Country of Publication
- GERMANY, WEST
Record 38 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa
line).
- Author
- Holinka CF; Hata H; Gravanis A; Kuramoto H; Gurpide E
- Address
-
- Source
- J Steroid Biochem, 1986 Nov, 25:5B, 781-6
- Abstract
- Estradiol (E2) stimulates the proliferation of human endometrial adenocarcinoma cells of
the Ishikawa line, which had been previously shown to respond to estrogen by increasing
their levels of progesterone receptor and the specific activities of DNA polymerase alpha
and alkaline phosphatase. Although E2 (10(-8) M) did not increase rates of proliferation
during the initial logarithmic growth period of the cultures under the chosen experimental
conditions (MEM with 15% charcoal-treated fetal bovine serum renewed every 2-3 days), it
sustained cell proliferation after about day 10, when parallel control cultures had
reached plateau cell densities. Cell proliferation in control cultures at plateau levels
was resumed when the hormone was added. Growth rates of cultures containing E2 from the
time of seeding and the proportion of quiescent cells, estimated by using a simple cell
kinetic model, decreased steadily with time. Ornithine
decarboxylase and DNA polymerase alpha activities, as well as estrogen receptor levels,
also decreased with time in culture. Ishikawa cells formed colonies in soft agar; colony
formation efficiencies were higher as the number of cells seeded was increased from 10,000
to 100,000 cells/6 cm dish, were not influenced by the addition of E2 to the medium
(10(-9) to 10(-5) M) and were markedly reduced by difluoromethylornithine
(10(-2) M), an effect that was counteracted by putrescine (25 X 10(-6) M).
- Language of Publication
- English
- Unique Identifier
- 87113988
- MeSH Heading (Major)
- Adenocarcinoma|ME/*PA; Estradiol|*PD; Uterine Neoplasms|ME/*PA
- MeSH Heading
- Cell Division|DE; Cell Line; DNA Polymerase II|ME; Female; Human; Kinetics; Mathematics;
Models, Biological; Ornithine Decarboxylase|ME; Receptors, Estrogen|ME; Support, U.S.
Gov't, P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0022-4731
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- EC 2.7.7.- (DNA Polymerase II); EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Receptors,
Estrogen); 50-28-2 (Estradiol)
Record 39 from database: MEDLINE
Return To The Top
Return To The Middle Of The Menu
- Title
- Sensory deprivation stress and supplemental stimulation in the rat pup and preterm human
neonate.
- Author
- Schanberg SM; Field TM
- Address
- Pharmacology Department, Duke University Medical School, Durham, NC 27710.
- Source
- Child Dev, 1987 Dec, 58:6, 1431-47
- Abstract
- This article reviews the literature and presents data from our laboratories on sensory
deprivation stress and supplemental stimulation of the rat pup and the preterm neonate.
The data suggest that the effects of maternal deprivation in the rat pup (suppression of
growth hormone release and protein synthesis) are regulated by a specific form of tactile
stimulation: only brush stroking of maternally deprived rat pups returned growth
parameters to normal; other forms of stimulation, including kinesthetic and vestibular
stimulation, were ineffective in restoring normal functions. Other data are presented
demonstrating that very small preterm neonates given tactile-kinesthetic stimulation gain
more weight per day, spend more time awake and active, and show more mature habituation,
orientation, motor, and range of state behaviors on the Brazelton assessment.
- Language of Publication
- English
- Unique Identifier
- 88081823
- MeSH Heading (Major)
- Animals, Newborn|*PH; Infant, Premature|*PH; Sensory Deprivation|*PH
- MeSH Heading
- Animal; Arousal|PH; Body Weight; Human; Infant, Newborn; Kinesthesis|PH; Ornithine
Decarboxylase|ME; Rats; Somatotropin|ME; Support, U.S. Gov't, P.H.S.; Touch|PH
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0009-3920
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 9002-72-6 (Somatotropin)
Search Phrase: Ornithine .and. Pituitary
HealthGate Document
Record 1 from database: MEDLINE
Order full text for this document
- Title
- Sp1 affinity for GC-rich elements correlates with ornithine decarboxylase promoter
activity.
- Author
- al Asadi R; Yi EC; Merchant JL
- Address
- Division of Gastroenterology, University of Michigan, Ann Arbor, USA.
- Source
- Biochem Biophys Res Commun, 1995 Sep, 214:2, 324-30
- Abstract
- The highly conserved ornithine decarboxylase (E.C.4.1.1.17) promoter contains multiple
binding sites for Sp1 within the first 400 bp of the cap site. Therefore the ability of
individual Sp1 elements to confer transactivation alone or in combination was tested. We
show that different Sp1 sites vary in their affinity for Sp1 and that increasing affinity
correlates with enhancer activity. In addition, several adjacent Sp1 sites synergistically
enhanced promoter activity. Thus, the strength of promoter transactivation correlated with
both the number of GC-rich elements and their affinity for Sp1 protein.
- Language of Publication
- English
- Unique Identifier
- 95408254
Order full text for this document
- MeSH Heading (Major)
- Ornithine Decarboxylase|BI/*GE; Promoter Regions (Genetics)|*; Transcription Factor,
Sp1|*ME
- MeSH Heading
- Adenoma; Animal; Base Sequence; Binding Sites; Cell Line; Cell Nucleus|ME; Cytosine;
Guanine; Human; Molecular Sequence Data; Mutagenesis, Insertional;
Oligodeoxyribonucleotides; Oligonucleotide Probes; Pituitary Neoplasms; Rats; Recombinant
Proteins|ME; Support, Non-U.S. Gov't; Transfection; Tumor Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0006-291X
- Country of Publication
- UNITED STATES
Record 2 from database: MEDLINE
Order full text for this document
- Title
- Intrinsic and extrinsic factors in estrogen action in human breast cancer: role of
polyamines and pituitary factors.
- Author
- Shiu RP; Lima G; Leung CK; Dembinski TC
- Address
-
- Source
- J Steroid Biochem, 1986 Jan, 24:1, 133-8
- Abstract
- Although polyamines are important in regulating proliferation of mammalian cells, their
role in hormone induction of cell growth has not been delineated. In the
estradiol-responsive human breast cancer cell line, T-47D clone 11, estradiol (10(-10) M)
was able to stimulate cell proliferation and the activity of ornithine decarboxylase
(ODC), the first and rate-limiting enzyme in the biosynthesis of polyamines.
alpha-Difluoromethylornithine (DFMO), a specific inhibitor of ODC, blocked the
estradiol-induced cell proliferation and ODC activity. Exogenous addition of putrescine,
the natural product of ODC, rescued the inhibitory effect of DFMO. In addition, DFMO
abolished the estradiol-induced growth of several other estrogen-responsive human breast
cancer cell lines but did not affect the growth of hormone-independent cell lines.
Further, a serum factor was found to be required for estradiol to exert its effect. To
gain insight into the nature of this and possibly other extrinsic factors involved, the
effect of estradiol on the proliferation of T-47D cells transplanted into athymic nude
mouse was evaluated. In this in vivo system, estradiol alone produced only moderate growth
of the human breast tumor. The simultaneous transplantation of a prolactin (PRL)- and
growth hormone (GH)-secreting rat pituitary tumor or normal rat pituitary glands at a
different site dramatically potentiated the effect of estradiol on the growth of the
breast tumor xenograft. Purified PRL or GH were without effect, indicating that the active
pituitary factor is neither PRL nor GH. Further, conditioned medium from rat pituitary
tumor cells potentiated the mitogenic effect of estradiol on T-47D and several other
estrogen receptor-positive human breast cancer cell lines in vitro under serum-free
condition. In conclusion, we have identified both intrinsic (polyamines) and extrinsic
(pituitary/serum) factors that are importance for estrogen to exert its mitogenic action.
The next goal will be to elucidate the mechanisms of action of these molecules in the
modulation of estrogen action.
- Language of Publication
- English
- Unique Identifier
- 86201682
Order full text for this document
- MeSH Heading (Major)
- Breast Neoplasms|*PA; Estrogens|*PD; Pituitary Gland|*PH; Polyamines|*ME
- MeSH Heading
- Animal; Cell Line; Drug Synergism; Female; Human; Mice; Mice, Nude; Neoplasm
Transplantation; Ornithine|AA/PD; Ornithine Decarboxylase|AN; Pituitary Neoplasms|SE;
Support, Non-U.S. Gov't; Transplantation, Heterologous
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0022-4731
- Country of Publication
- ENGLAND
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Estrogens); 0 (Polyamines); 70052-12-9
(Eflornithine); 7006-33-9 (Ornithine)
Record 3 from database: MEDLINE
Order full text for this document
- Title
- Synthesis and biological evaluation of superactive agonists of growth hormone-releasing
hormone.
- Author
- Izdebski J; Pinski J; Horvath JE; Halmos G; Groot K; Schally AV
- Address
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70146,
USA.
- Source
- Proc Natl Acad Sci U S A, 1995 May, 92:11, 4872-6
- Abstract
- Analogs of the 29 amino acid sequence of human growth hormone-releasing hormone (hGH-RH)
with agmatine (Agm) in position 29, desaminotyrosine (Dat) in position 1, norleucine (Nle)
in position 27, and L-alpha-aminobutyric acid (Abu) in position 15 have been synthesized,
and their biological activity was evaluated. Some peptides contained one or two residues
of ornithine (Orn) instead of Lys in positions 12 and 21 and additional replacements in
positions 8 and 28. All analogs were found to be more potent than hGH-RH-(1-29)-NH2 in the
superfused rat pituitary cell system. In tests in vivo in rats after subcutaneous
administration, the analogs JI-22, [Dat1, Orn12,21, Abu15, Nle27, Agm29]hGH-RH-(1-29);
JI-34, [Dat1, Orn12,21,Abu15,Nle27, Asp28, Agm29]hGH-RH-(1-29); JI-36, [Dat1, Thr8,
Orn12,21, Abu15,Nle27,Asp28,Agm29]hGH-RH-(1-29); and JI-38, [Dat1,Gln8,
Orn12,21,Abu15,Nle27,Asp28,Agm29]hGH-RH-(1 -29) displayed a potency 44.6,80.9,95.8, and
71.4 times greater, respectively, than that of hGH-RH-(1-29)-NH2 at 15 min and 217.1,
89.7, 87.9, and 116.8 times greater at 30 min. After intravenous administration, JI-22,
JI-36, and JI-38 were 3.2-3.8 times more potent than hGH-RH-(1-29)-NH2 at 5 min and
6.1-8.5 times more active at 15 min. All analogs were found to have higher binding
affinities for GH-RH receptors on rat pituitary cells than hGH-RH-(1-29)-NH2. Because of
high activity and greater stability, these analogs could be considered for therapy of
patients with growth hormone deficiency.
- Language of Publication
- English
- Unique Identifier
- 95281558
Order full text for this document
- MeSH Heading (Major)
- Oligopeptides|CS/*PD; Pituitary Gland|DE/*SE; Somatotropin|BL/*SE;
Somatotropin-Releasing Hormone|*AA/AG/*CS/PD
- MeSH Heading
- Amino Acid Sequence; Animal; Comparative Study; Human; In Vitro; Male; Molecular
Sequence Data; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide|ME; Receptors,
Pituitary Hormone-Regulating Hormone|ME; Structure-Activity Relationship; Support, U.S.
Gov't, Non-P.H.S.
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0027-8424
- Country of Publication
- UNITED STATES
Record 4 from database: MEDLINE
Order full text for this document
- Title
- Ornithine decarboxylase immunoreactivity in the pituitary gland. A comparative
lightmicroscopical study.
- Author
- Müller M; Bernstein HG; Aurin H; Järvinen M; Pajunen AE
- Address
- Institute of Neurobiology and Brain Research, Magdeburg, Germany.
- Source
- Cell Mol Biol, 1991, 37:2, 119-24
- Abstract
- In the present study efforts are made to localize ornithine decarboxylase enzyme
protein--the key enzyme of polyamine biosynthesis--in the adenohypophysis of different
vertebrates by means of immunocytochemistry. The antigenic expression of ornithine
decarboxylase was revealed in the pituitary of the clawed frog (Xenopus laevis D.), but
not in rat and human adenohypophysis. The immunocytochemical results are compared with the
staining pattern of the periodic acid-Schiff-reaction. No correlation between these
results and the immunocytochemically obtained data has been found. Conclusions are drawn
from the location of the enzyme and possible phylogenetic and humoral regulation
mechanism.
- Language of Publication
- English
- Unique Identifier
- 91347299
Order full text for this document
- MeSH Heading (Major)
- Ornithine Decarboxylase|*AN; Pituitary Gland|*EN; Pituitary Gland, Anterior|*EN
- MeSH Heading
- Animal; Comparative Study; Cytoplasm|EN; Human; Immunoenzyme Techniques; Rats; Rats,
Inbred Strains; Xenopus laevis
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0145-5680
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase)
Record 5 from database: MEDLINE
Order full text for this document
- Title
- Pancreatic tumoral cell line AR42J: an amphicrine model.
- Author
- Christophe J
- Address
- Department of Biochemistry and Nutrition, Medical School, UniversitÆe Libre de
Bruxelles, Belgium.
- Source
- Am J Physiol, 1994 Jun, 266:6 Pt 1, G963-71
- Abstract
- AR42J cells derive from azaserine-induced malignant nodules from the rat pancreas. They
differ from normal acinar cells for at least three reasons: 1) they proliferate rapidly;
2) they synthesize, store, and secrete digestive enzymes but the regulation of their
exocrine function is abnormal, from the emergence of atypical receptors (e.g.,
cholecystokinin octapeptide type B and pituitary adenylate cyclase-activating polypeptide
type I receptors) to unusual inositol phosphate metabolism and cytoskeleton
disorganization; and 3) they possess an added neuroendocrine-regulated pathway
characterized by voltage-sensitive ionic currents, post-translational processing of
peptidic prohormones (and possibly autocriny), and the release of small neurotransmitters
(gamma-aminobutyric acid, glycine, and glutamic acid). These amphicrine cells represent,
therefore, a cancerous version of the primordial pancreatic ductular epithelium.
Dexamethasone favors their differentiation toward the exocrine phenotype. The mitogenic
pathway is favored by the occupancy of receptor tyrosine kinases, adenosine 3',5'-cyclic
monophosphate, ornithine decarboxylase expression, and Na(+)-H+ exchange. Somatostatin
opposes proliferation through protein phosphatases.
- Language of Publication
- English
- Unique Identifier
- 94295709
Order full text for this document
- MeSH Heading (Major)
- Pancreatic Neoplasms|*SE; Tumor Cells, Cultured|*
- MeSH Heading
- Animal; Cell Differentiation; Dexamethasone|PD; Digestion; Enzymes|SE; Exocytosis;
G-Proteins|PH; Human; Ion Channels|ME; Receptors, Cholecystokinin|ME; Signal Transduction;
Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0002-9513
- Country of Publication
- UNITED STATES
Record 6 from database: MEDLINE
Order full text for this document
- Title
- Mechanism of action and pure antiandrogenic properties of flutamide.
- Author
- Labrie F
- Address
- Medical Research Council Group, Le Centre Hospitalier de l'Universite Laval Research
Center, Laval University, Québec City, Canada.
- Source
- Cancer, 1993 Dec 15, 72:12 Suppl, 3816-27
- Abstract
- Although treatment of intact adult male rats with the pure antiandrogen flutamide or a
luteinizing hormone-releasing hormone (LHRH) agonist alone leads to partial inhibition of
ventral prostate weight, maximal inhibition is achieved by combination of the two drugs.
Potentializing effects of the two compounds were observed even on prostatic ornithine
decarboxylase activity. Because LHRH agonists are widely used to achieve medical
castration in men treated for prostate cancer, it is of interest to observe that in the
dog, known for being the best model for studies of the action of LHRH agonists, flutamide
does not interfere with the potent desensitizing action of the LHRH agonist on pituitary
LH secretion, thus supporting the combined use of flutamide with an LHRH agonist for
maximal androgen blockade without loss of efficiency of the LHRH agonist. Because prostate
cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we
analyzed the effect of combined antiandrogen therapy on parameters more sensitive to
androgens than ventral prostatic weight itself. In agreement with its pure antiandrogenic
characteristics, flutamide alone has no stimulatory effect on the intraprostatic level of
mRNA encoding the C1 or C3 component of prostatic binding protein (PBP), whereas
cyproterone acetate (CPA), megestrol acetate (MEG), and, especially, medroxyprogesterone
acetate (MPA) markedly stimulate PBP-C1 and PBP-C3 mRNA levels, an effect reversed by
flutamide, thus further supporting the intrinsic androgenic activity of all these
steroidal derivatives. Similar androgenic effects of the steroidal derivatives were
observed on prostatic ornithine decarboxylase activity. Androgen-sensitive Shionogi tumor
cells were then used to assess the antiandrogenic/androgenic properties of flutamide and
the above-indicated steroidal derivatives. MPA, MEG, CPA as well as
spironolactone-stimulated cell proliferation under both in vivo and in vitro conditions,
thus illustrating the intrinsic androgenic activity of all these compounds. Flutamide was
inactive by itself and reversed the stimulatory effect of all other compounds, thus
indicating its pure antiandrogenic activity. Although castration reduces intraprostatic
dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the
concentration remains at about 50% of the value found in intact men after castration, thus
indicating an important contribution of the adrenals to DHT in the human prostate, a
finding that requires the addition of an antiandrogen to block the action of this
important amount of DHT remaining after castration.
- Language of Publication
- English
- Unique Identifier
- 94073829
Order full text for this document
- MeSH Heading (Major)
- Androgen Antagonists|*PD; Flutamide|AD/*PD
- MeSH Heading
- Androgen-Binding Proteins|GE; Animal; Antineoplastic Agents, Combined|PD; Comparative
Study; Gonadorelin|AA/AD/PD; Human; LH|BL; Male; Orchiectomy; Ornithine Decarboxylase|ME;
Prostate|DE/EN; Prostatic Neoplasms|DT/PA; RNA, Messenger|AN; Stanolone|AN; Tumor Cells,
Cultured|DE
- Publication Type
- JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL
- ISSN
- 0008-543X
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (prostatic binding protein); 0 (Androgen
Antagonists); 0 (Androgen-Binding Proteins); 0 (Antineoplastic Agents, Combined); 0 (LHRH,
Trp(6)-des-GlyNH2(10)-); 0 (RNA, Messenger); 13311-84-7 (Flutamide); 33515-09-2
(Gonadorelin); 521-18-6 (Stanolone); 9002-67-9 (LH)
Record 7 from database: MEDLINE
Order full text for this document
- Title
- Activity of ornithine decarboxylase (ODC) and polyamine levels as biochemical markers of
malignancy in human brain tumors.
- Author
- Ernestus RI; Röhn G; Schröder R; Klug N; Hossmann KA; Paschen W
- Address
- Max-Planck-Institute for Neurological Research, Department of Experimental Neurology,
Cologne, Germany.
- Source
- Acta Histochem Suppl, 1992, 42:, 159-64
- Abstract
- The content of the polyamines putrescine, spermidine and spermine, and the activity of
their metabolic key enzyme ornithine decarboxylase (ODC) were measured in tissue samples
obtained during operation of 45 patients with primary or recurrent gliomas, meningiomas
and pituitary adenomas. Biochemical analysis and histopathological classification were
carried out in the same tumor samples. In benign tumors ODC activity was less than 10
nmol/g/h, whereas in malignant gliomas values up to 34 nmol/g/h were observed. In rapidly
growing tumors pronounced heterogeneity was observed with high values in solid tumor parts
and low values in necrotic areas. Thus, high ODC activity represents a reliable
biochemical marker of malignancy in brain tumors, but low values do not prove benignity.
- Language of Publication
- English
- Unique Identifier
- 92262733
Order full text for this document
- MeSH Heading (Major)
- Biogenic Polyamines|*AN; Brain Neoplasms|*CH/PA; Ornithine Decarboxylase|*AN; Tumor
Markers, Biological|*AN
- MeSH Heading
- Adenoma|CH/PA; Brain|EN/PA; Brain Chemistry|PH; Glioma|CH/PA; Human; Meningeal
Neoplasms|CH/PA; Meningioma|CH/PA; Neoplasm Recurrence, Local; Support, Non-U.S. Gov't
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0567-7556
- Country of Publication
- GERMANY
- CAS Registry/EC Number
- EC 4.1.1.17 (Ornithine Decarboxylase); 0 (Biogenic Polyamines); 0 (Tumor Markers,
Biological)
Record 8 from database: MEDLINE
Order full text for this document
- Title
- Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic
moieties.
- Author
- Janáky T; Juhász A; Rékási Z; Serfözö P; Pinski J; Bokser L; Srkalovic G;
Milovanovic S; Redding TW; Halmos G; et al
- Address
- Endocrine, Polypeptide and Cancer Institute, Tulane University School of Medicine, New
Orleans, LA 70146.
- Source
- Proc Natl Acad Sci U S A, 1992 Nov 1, 89:21, 10203-7
- Abstract
- Five hexapeptide and heptapeptide analogs of luteinizing hormone-releasing hormone
(LH-RH) were synthesized for use as carriers for cytotoxic compounds. These short analogs
were expected to enhance target selectivity of the antineoplastic agents linked to them.
Native LH-RH-(3-9) and LH-RH-(4-9) containing D-lysine and D-ornithine at position 6 were
amidated with ethylamine and acylated on the N terminus. The receptor-binding affinity of
one hexapeptide carrier AJ-41 (Ac-Ser-Tyr-D-Lys-Leu-Arg-Pro-NH-Et) to human breast cancer
cell membranes was similar to that of [D-Trp6]LH-RH. Alkylating nitrogen mustards
(melphalan, Ac-melphalan), anthraquinone derivatives including anticancer antibiotic
doxorubicin, antimetabolite (methotrexate), and cisplatin-like platinum complex were
linked to these peptides through their omega-amino group at position 6. The hybrid
molecules showed no LH-RH agonistic activity in vitro and in vivo but had nontypical
antagonistic effects on pituitary cells in vitro at the doses tested. These analogs showed
a wide range of receptor-binding affinities to rat pituitaries and cell membranes of human
breast cancer and rat Dunning prostate cancer. Several of these conjugates exerted some
cytotoxic effects on MCF-7 breast cancer cell line.
- Language of Publication
- English
- Unique Identifier
- 93066208
Order full text for this document
- MeSH Heading (Major)
- Antineoplastic Agents|*PD; Cell Survival|*DE; Gonadorelin|*AA/CS/ME/*PD;
Oligopeptides|CS/*PD
- MeSH Heading
- Amino Acid Sequence; Animal; Anthraquinones|PD; Breast Neoplasms|ME; Cell Membrane|ME;
Cisplatin|PD; Comparative Study; Doxorubicin|PD; Female; Human; LH|BL; Male; Melphalan|PD;
Methotrexate|PD; Molecular Sequence Data; Orchiectomy; Pituitary Gland|ME; Prostatic
Neoplasms|ME; Rats; Receptors, LHRH|ME; Structure-Activity Relationship; Support, U.S.
Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.; Tumor Cells, Cultured
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0027-8424
- Country of Publication
- UNITED STATES
- CAS Registry/EC Number
- 0 (Anthraquinones); 0 (Antineoplastic Agents); 0 (Oligopeptides); 0 (Receptors, LHRH);
148-82-3 (Melphalan); 15663-27-1 (Cisplatin); 17241-59-7 (2-(hydroxymethyl)anthraquinone);
23214-92-8 (Doxorubicin); 33515-09-2 (Gonadorelin); 59-05-2 (Methotrexate); 9002-67-9 (LH)
Record 9 from database: MEDLINE
Order full text for this document
- Title
- Comparison of growth hormone response to growth hormone-releasing factor 1-44 according
to the combined study of sleep secretion with the responses to pharmacologic stimuli.
- Author
- Garnier P; Liapi C; Raynaud F; Evain-Brion D
- Address
- Fondation de Recherche en Hormonologie, Fresnes, France.
- Source
- Horm Res, 1987, 28:1, 13-9
- Abstract
- The growth hormone (GH) response to GH-releasing factor (GRF) was studied in 54 severely
growth-retarded patients (-2.1 to -6.5 SD) aged from 5 to 20 years (32 males and 22
females), among whom 34 were prepubertal and 20 at early pubertal stages. The patients
were also submitted to a standard evaluation of their GH secretion, consisting of at least
two classical pharmacologic stimulation (CPS) tests, such as ornithine, arginine and/or
insulin, and one study of the GH sleep secretion (SS). The results of the standard
evaluation allowed to distinguish 5 groups: (I) endocrinologically normal (n = 26); (II)
completely GH deficient (n = 5); (III) partially GH deficient (n = 8); (IV) dissociated GH
secretions with normal SS (n = 9), and (V) dissociated GH secretions with low SS (n = 6).
The GH responses to GRF were correlated with both responses to CPS and SS. There was a
large overlap of the individual responses to GRF between the 5 groups, but the mean
responses in groups II, IV and V were significantly lower than in group I. Furthermore,
the mean responses of groups IV and V were in the lower range of the normal. It is
concluded that the GRF test may be useful to ascertain the diagnosis of functional or
partial GH deficiency when the responses to CPS and SS are dissociated.
- Language of Publication
- English
- Unique Identifier
- 88197053
Order full text for this document
- MeSH Heading (Major)
- Growth Disorders|*ME; Sleep|*PH; Somatotropin|DF/*SE; Somatotropin-Releasing Hormone|*DU
- MeSH Heading
- Adolescence; Adult; Child; Child, Preschool; Comparative Study; Female; Human; Male;
Pituitary Function Tests|MT; Pituitary Gland|DE/SE
- Publication Type
- JOURNAL ARTICLE
- ISSN
- 0301-0163
- Country of Publication
- SWITZERLAND
- CAS Registry/EC Number
- 9002-72-6 (Somatotropin); 9034-39-3 (Somatotropin-Releasing Hormone)
Return to the HealthGate
Home Page.
Send comments to:support@healthgate.com
This page was last updated at: Saturday, June 27, 1998 04:48 PM
Copyright
©1996 HealthGate Data Corp., All rights reserved.
SUBSCRIBE:
The Wednesday Letter is a free electronic monthly newsletter written and published by Karl Loren.
You can view more than 50 back issues of this publication by clicking here.
The Wednesday Letter subscription list is maintained on a secure server, no name is ever given or sold to anyone, and it is never used except for this Newsletter.
It is automatically published on the Tuesday night just before the first Wednesday of every month.
You can subscribe to this free monthly electronic letter by entering your eMail address and name below.
You will then automatically receive a request for confirmation, sent to whatever address you have entered.
If you do NOT receive this confirmation request, then you will not be subscribed.
There may have been an error with your address and you should resubmit.
The letter is never sent twice to the same address -- so you do not have to worry about a duplicate subscription.
When you receive this confirmation request you must reply to it, or your subscription will not become active.
No one can subscribe your name, and address, without you being notified, and if you get an unwanted notice of subscription you only need to DO NOTHING and the subscription will NOT be active.
REMOVAL:
You can remove yourself from the subscription list in several different ways.
Click here to read about this entire newsletter system.
Every edition of The Wednesday Letter is delivered to your address with YOUR name and address in view on the letter, with a link that allows you to remove THAT name from the subscription list.
If you try to send this removal message from an address different from the one you used to send in your original confirmation, then you will get a warning notice first, sent to the subscription address, asking you to confirm that you want to be removed from the list -- by replying to THAT request for confirmation, you will then be automatically removed.
Thus, no one else can unsubscribe you, from some other computer, without your knowledge.
But, if you send in the unsubscribe notice from the same machine used to receive the Letter, then the removal from the subscription list is automatic.
Personal Message:
When you send a personal message to Karl Loren, you will receive a personal reply as per his instructions.
Karl pledges that every personal message will get a personal answer. When you provide your mail address, we will send you free information including our free catalog and a cassette tape lecture by Karl Loren about heart disease, no charge, by mail, even if outside the US.
You can select particular information you would like to receive, along with the free cassette tape and catalog.
You can reach Vibrant Life in many ways, including by mail to
Vibrant Life, 2808 N. Naomi St., Burbank, CA 91504.
Within the US and Canada, use
the toll free number: (800) 523-4521,
the local number: (818) 558-1799,
the FAX: (818) 558-7299,
eMail to kimberly@oralchelation.com
or any one of the hundreds of message forms throughout the 50 web sites.
Vibrant Life normally ships the same day we get an order.
There are message forms on each of the 100,000+ pages on this and other sites where you can communicate with Vibrant Life.
Check out our companion site, at: http://www.oralchelation.net
where Karl's 2000 page book is published. Karl Loren is the author and
webmaster for this BOOK, as well as
for another web site about ORAL CHELATION.
His personal philosophical articles are at PHILOSOPHY.
Copyright © May 10, 2012 12:06 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED.
Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions:
One, that some form of copyright notice is included in every copy distributed or copied,
showing the copyright belonging to Vibrant Life, Burbank, CA, at
www.oralchelation.com .
The second condition is that the material is not to be used for any purpose contrary to
the purposes and objectives of this site.
This permission does not extend to materials on this site which are copyrighted by others.